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Chien-Wei Chiang 
TRANSLATIONAL HIGH-DIMENSIONAL DRUG INTERACTION DISCOVERY AND VALIDATION 
USING HEALTH RECORD DATABASES AND PHARMACOKINETICS MODELS 
Polypharmacy leads to increased risk of drug-drug interactions (DDI’s). In this 
dissertation, we create a database for quantifying fraction of metabolism (fm) of CYP450 
isozymes for FDA approved drugs. A reproducible data collection protocol was 
developed to extract key information from publicly available in vitro selective CYP 
enzyme inhibition studies. The fm was then estimated from the curated data. Then, 
proposed a random control selection approach for nested case-control design for 
electronical health records (HER) and electronical medical records (EMR) databases. By 
relaxing the matching by case’s index time restriction, random control dramatically 
reduces the computational burden compared with traditional control selection 
approaches. Using the Observational Medical Outcomes Partnership gold standard and 
an EMR database, random control is demonstrated to have better performances as well. 
Finally, combining epidemiological studies and pharmacokinetic modeling with fm 
database, we detected and evaluated high-dimensional drug-drug interactions among 
thirty high frequency drugs. Multi-drug combinations that increased risk of myopathy 
were identified in the FAERS and EMR databases by a mixture drug-count response 
model (MDCM) model. Twenty-eight 3-way and 43 4-way DDI’s increased ratio of area 
under plasma concentration–time curve (AUCR) >2-fold and had significant myopathy 
risk in both databases. The predicted AUCR of omeprazole in the presence of 
fluconazole and clonidine was 9.35; and increased risk of myopathy was 6.41 (LFDR = 
 v 
0.002) in FAERS and 18.46 (LFDR = 0.005) in EMR. We demonstrate that combining 
health record informatics and pharmacokinetic modeling is a powerful translational 
approach to detect high-dimensional DDI’s.  
Huanmei Wu, Ph.D., Co-Chair 
Lang Li, Ph.D., Co-Chair  
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Chapter 1. Introduction 
1.1 Adverse Drug event and Drug-drug interaction 
Adverse drug events (ADEs) are considered to be a significant challenge for 
current clinical practices. Drug-drug interactions (DDIs) are a common cause of adverse 
drug events (ADE) (Hajjar, Cafiero, & Hanlon, 2007; U.S. Department of Health and 
Human Services; L. Zhang, Zhang, Zhao, & Huang, 2009). In the United States alone, each 
year an estimated 195,000 hospitalizations and 74,000 emergency room visits are the 
result of DDIs. National Health and Nutrition Examination Survey data published in 2010 
(Gu, Dillon, & Burt, 2010) showed that patients, who used two or more prescription 
drugs, increased from 25.4% to 31.2% in ten years since 1999. In particularly, among the 
older population, more than 64% took three or more prescription drugs, and 37% took 
five or more prescription drugs (Gu et al., 2010). In FDA Adverse Event Reporting System 
(FAERS) data, there are 35% reports that include three or more prescription drugs in 
each report, and 20% reports have five or more prescription drugs. Though ADEs can be 
detected in either pre-marketing clinical trials or post-marketing surveillances, most ADE 
knowledges are revealed in the post-marketing stage. This is because post-marketing 
stage allows larger population and prolonged follow up (Harpaz et al., 2012). 
Additionally, unlike pre-marketing clinical trials, drugs are administered without 
stringent inclusion/exclusion criteria.  
1.2 Fraction of metabolism and CYP P450  
There are some widely-used database for drug metabolism: a) DrugBank 
(Wishart et al., 2006), which is a comprehensive database which combines detailed drug 
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(i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug 
target (i.e. sequence, structure, and pathway) information; b) Transformer (the former 
Super CYP) (Preissner et al., 2010), which integrates Cytochrome P450 enzyme 
interactions and some pharmacological information; c) DIDB (Hachad, Ragueneau-
Majlessi, & Levy, 2010), which can evaluate the impact of DDI in the clinic by in vitro and 
in vivo DDI data, few fm data can be found. 
The contributions of CYPs for a drug’s metabolism can be estimated as the 
change in AUC or clearance in the absence and presence of a co-administered selective 
inhibitor through an in vivo approach (Creighton et al., 2008; Le Coutre et al., 2008). fm 
can be also estimated via a pharmacogenetics study where it can be calculated from the 
fold-change in exposure of a victim drug in extensive metabolizers (EMs) compared to 
poor metabolizers (PMs) (Ito, Hallifax, Obach, & Houston, 2005). Third, human 14C or 3H-
ADME studies, which measure the concentration of the radiolabeled unchanged drug 
and its metabolites in plasma, urine and feces, is also regarded as a valuable approach 
and clinical pharmacokinetics study to estimate the metabolic pathways of a drug 
(Bohnert et al., 2016; Rodrigues, Winchell, & Dobrinska, 2001). Several other in vitro 
methods have been developed to determine the contribution of individual cytochrome 
P450 isozymes in a drug’s metabolism. Substrate depletion in human liver microsomes 
(HLM) is one method that the drug is incubated with or without specific CYP450 
selective inhibitors (Huskey, Dean, Miller, Rasmusson, & Chiu, 1995). Comparing to the 
metabolism rate, Vmax/Km, of the substrate without any inhibitor, the percent 
inhibition of this CYP pathway by the CYP-selective chemical inhibitor reflects the 
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contribution of this CYP towards the substrate’s metabolism. Ideally chemical inhibitors 
should be potent, selective and metabolically stable. Substrate depletion can also be 
incubated with individual recombinant enzymes isoforms (Z. M. Li, Guo, & Ren, 2016). 
This approach estimates the metabolism rate, Vmax/Km, of the substrate in 
recombinant human (rh) CYP isoforms, and scales the rhCYP Vmax/Km to HLM CLint via a 
RAF/ISEF approach (Bohnert et al., 2016). Each isozymes contribution is estimated as the 
percent contribution of each CYP enzyme towards the total HLMCLint. 
1.3 Evaluate Adverse Drug Event signal 
1.3.1 Evaluation method 
For a drug-ADE pair of interest, either univariate analyses or multivariate 
analyses can be used for signal detection. Under univariate analyses, available samples 
are usually summarized by a 2-by-2 contingency table, in which contains the frequencies 
classified by the usage of the drug (yes/no) and the occurrence of the ADE (yes/no). The 
outcome is the frequency that this drug-ADE pair is co-occurred, and the expectation is 
the expected frequency of this drug-ADE pair under the assumption of no association. 
Univariate analyses are also known as disproportion analysis (DPA), as they quantify ADE 
signals by the outcome to expectation ratio (i.e. relative risk) or its variants. Frequentist 
DPAs include proportional reporting ratio (PRR) and reporting odds ratio (ROR) (Evans, 
Waller, & Davis, 2001; van Puijenbroek et al., 2002). While, the empirical Bayesian 
geometric mean (EBGM) is an empirical Bayesian DPA and the information component 
(IC) is a Bayesian DPA (Bate et al., 1998; DuMouchel, 1999). DPAs are demonstrated to 
have promising performances and are computationally efficient (Harpaz et al., 2013). 
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However, confounding bias, especially confounding by co-medication, may cause biased 
disproportionality measurements of the true association. Typical multivariate analyses 
utilize multiple logistic regression (MLR) or regulated logistic regression (RLR) models to 
adjust potential confounding variables (i.e. co-medications). Besides this advantage, 
practices of MLR/RLR are often challenged by considerable larger sample sizes of 
pharmacovigilance databases. For instance, regular computers cannot fit MLR over 
millions of samples. In a summary, DPAs are powerful tools for large scale signal 
detection, as they can be applied to multiple ADEs together (Harpaz et al., 2012). 
Multivariate analyses that models an ADE and all co-medications are preferred for 
specific hypotheses testing.  
1.3.2 Epidemiology Designs 
In SRS, temporal information is omitted and each sample contains the ADE and 
drug status (Yes/No). Such a structure allows both multivariate analyses and DPAs to be 
applied directly to SRS. However, in EMR/HER database, patients are usually followed 
longitudinally with detailed temporal information about medications and phenotypes. 
As a consequence, EMR/EHR analyses typically require sophisticated epidemiology 
designs such as cohort design, self-controlled design, and nested case-control design 
(Hennessy et al., 2016). These epidemiology designs have been widely utilized for 
EMR/EHR analyses. Cohort design identifies exposure and non-exposure cohorts. ADE 
risks are estimated within each cohort, and the drug-ADE associations are estimated by 
the RR. The non-exposure cohort can be selected based on estimated propensity scores 
to ensure their similarities with the exposure cohort. For instance, Tatonetti et al. 
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assumes the latent cofounders can be characterized by co-medications, and propensity 
scores are then calculated by modeling the co-medications based on such assumption 
(Tatonetti, Ye, Daneshjou, & Altman, 2012). For the cases and their matched controls, 
nested case-control design uses a predefined window to examine drug exposures. For a 
case, usually 4 – 10 controls are selected. The controls are usually matched with the 
case’s index date and risk factors (Schneeweiss, 2010). Additionally, they are case-free 
up to the case’s index time. Thus, such controls are also named as at risk or dynamic 
control. If the controls are restricted to be case free for the entire follow up, this type of 
controls is known as super control. Some example of application of nested case-control 
designs includes Brauer et al., La gamba et al. and Lee et al. (Brauer et al., 2014; La 
Gamba et al., 2017; Lee et al., 2011). In real applications, EMR/EHR databases may 
contain up to millions of patients. Such a sample size become an obstacle for the 
application of epidemiology designs to conduct large scale (i.e. drug wide and ADE wide) 
ADE signal detection. For instance, as we mentioned above, fitting propensity score 
model over millions of samples cannot be accomplished by regular computers. 
Moreover, in EMR/EHR analyses, propensity scores will be time dependent, which 
further increased the computational burden. Though nested case-control design do not 
require complicated modelling, the matching process still computationally expensive.  
1.4 Evaluate Drug-drug interaction 
1.4.1 Clinical pharmacokinetic studies 
The translational significance of drug-drug interaction studies relies on both 
clinical and molecular pharmacology evidence. One salient example is that of breast 
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cancer hormonal therapy, tamoxifen. The formation of its active metabolite, endoxifen, 
was inhibited by concomitant selective serotonin reuptake inhibitor paroxetine in a 
clinical pharmacokinetics study (Stearns et al., 2003). In-vitro metabolism studies 
revealed that this is due to paroxetine’s strong inhibition of the tamoxifen bio-
transformation to endoxifen via the CYP2D6 pathway (Desta, Ward, Soukhova, & 
Flockhart, 2004). In a follow-up pharmacogenetic study, breast cancer patients with 
CYP2D6 loss function variants have a higher risk of disease relapse and a lower incidence 
of hot flush (Goetz et al., 2005). The clinical consequence of treating breast cancer and 
depression using tamoxifen and SSRIs was reviewed (Henry, Stearns, Flockhart, Hayes, & 
Riba, 2008), and called for further investigation. Another example is the sedation agent 
midazolam. Co-administration of midazolam and ergosterol synthesis inhibitor 
ketoconazole has been identified to reduced subjects’ cognitive function (Lam, Alfaro, 
Ereshefsky, & Miller, 2003). In clinical PK and in-vitro experiments, midazolam 
metabolism was inhibited by ketoconazole through the CYP3A pathway (Gascon & 
Dayer, 1991; Gorski, Hall, Jones, VandenBranden, & Wrighton, 1994), leading to 
increased midazolam exposure (Olkkola, Backman, & Neuvonen, 1994). 
1.4.2 Epidemiology and drug-drug-ADE associations 
As described by Hennessy and Flockhart (Hennessy & Flockhart, 2012), an 
integrated informatics, epidemiology, and pharmacology approach has the potential to 
accelerate the translational drug interaction studies. Pioneered by Tatonetti et al 
(Tatonetti et al., 2012), FAERS and electronic medical records were utilized to generate 
and validate Drug-ADE and drug-drug-ADE associations. In a follow-up study, 
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Lorberbaum et al demonstrated that patients co-administrated ceftriaxone and 
lansoprazole were 1.4 times as likely to have a prolong QT prolongation than the 
administrated single drug in both EMR and FAERS data. Further validation showed that 
ceftriaxone/lansoprazole drug interaction was due to hERG channel blocker in a patch-
clamp experiment system (Lorberbaum et al., 2016). Duke et al proposed a text mining 
strategy for DDI molecular pharmacology evidence discovery from the public literature 
(Duke et al., 2012), which discovered 13,197 potential DDIs. In the follow-up in-vitro 
study, Han et al validated the loratadine-simvastatin myotoxicity interaction, and its 
increased myopathy risk in both EMR and FAERS databases (Han et al., 2015). Similarly, 
Schelleman et al examined the increased risk of hypoglycaemia with co-administration 
of fibrates and statins in sulfonylurea users in a pharmaco-epidemiology study 
(Schelleman et al., 2014). This DDI was further evaluated in an in-vitro in-vivo 
extrapolation (IVIVE) pharmacokinetics model. 
1.4.3 In-vitro In-vivo extrapolation (IVIVE) pharmacokinetics model 
To use IVIVE pharmacokinetics model, drugs pharmacokinetics properties have 
been studied, especially metabolism. The majority of small molecule drugs are catalyzed 
by Cytochrome P450 (CYP) enzymes, which are located in the hepatic endoplasmic 
reticulum (Renwick, 1999; Shen, Kunze, & Thummel, 1997). Many factors can alter 
hepatic drug metabolism, including genetic polymorphisms, disease and concomitant 
medications, foods etc.(Eichelbaum, Ingelman-Sundberg, & Evans, 2006; Ereshefsky, 
1996; Shah & Smith, 2015). Among these factors, concomitant medications are very 
important because of poly-pharmacy (Admassie, Melese, Mequanent, Hailu, & Srikanth, 
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2013; Fitzgerald, 2009; Hanlon et al., 1996; Rosholm, Bjerrum, Hallas, Worm, & Gram, 
1998; Sasaki et al., 2013). Therefore, it is highly important to quantify the contribution 
of different metabolism pathways in order to predict drug exposure change after 
inhibitions (D. Zhang, Zhu, & Humphreys, 2007). The term fm, is defined as the fraction 
of drug metabolized by an enzyme. There are multiple ways that fm can be estimated 
through clinical pharmacokinetics studies or in vitro pharmacokinetics experiments. 
1.5 Proposed Solutions  
1.5.1 Scope of Aim 1: Drug fm database 
The purpose of the aim is to prepare the required pharmacokinetic parameters 
that can be used to in an in-vitro in-vivo extrapolation (IVIVE) pharmacokinetics model. 
The fm database was curated from published articles indexed in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/). In drug selection, 237 FDA approved cancer 
drugs were identified in DrugBank and National Cancer Institute (NCI). The next stage is 
the key word search, including cancer drug names, “cytochrome P450”, “human liver 
microsomes” and/or “metabolism”. The detail of this aim will be described in Chapter 2. 
1.5.2 Scope of Aim 2: Random control approach based nested case-control design 
We propose a control selection approach for nested case-control design which 
will be computationally efficient for large scale ADE signal detection. We name the 
proposed controls as random control, as both the patients and their index time are 
randomly selected. The key difference between random control and super/dynamic 
control is the relaxation of matching by the index time condition. The performances of 
nested case-control design by using super, dynamic and random control will be 
 9 
evaluated by the Observational Medical Outcomes Partnership (OMOP) gold standard 
(Ryan et al., 2012). The detail of this aim will be described in Chapter 3. 
1.5.3 Scope of Aim 3: High-dimensional drug interaction 
We will use this newly developed mixture drug-count response model (MDCM) 
to detect high-dimensional drug-drug interactions (HDDIs) that lead to increased risk of 
myopathy in two independent databases: Indiana Network of Patient Care - CDM (INPC-
CDM) electronic medical record and FAERS (Chiang et al., 2017). Using in vitro 
cytochrome P450 (CYP) inhibition data and mechanistic static in vitro in vivo DDI 
predictions, we evaluate the potential pharmacological mechanisms of these HDDIs. The 
detail of this aim will be described in Chapter 4. 
1.6 Impact of Project 
1.6.1 Impact of Aim 1 
In this research, we present our initial effort in developing a drug fm database. 
We focus on the fm data collected and estimated from in vitro inhibition studies of 
human liver microsomes, including both metabolites formation and substrate depletion 
studies. There are additional data, such as pharmacogenetics clinical PK studies and 
drug interaction clinical PK studies, in which fm can also be estimated. These fm 
estimates could be more accurate than the fm estimates from in vitro studies. 
This database has been demonstrated successfully to predict the drug-drug 
interactions regarding several CYP isozymes. We believe that the public availability of 
this database will facilitate pharmacokinetics research. 
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1.6.2 Impact of Aim 2 
In this study, we propose a random control approach based nested case-control 
design for EMR/EHR analyses. In random controls, patients will be randomly selected to 
from a control pool, and index times are randomly selected as well. Hence, the risk 
factor evaluation is only limited to the control pool at the index times. Additionally, the 
control pools can be used for multiple ADEs. As a consequence, random control 
selection is efficient for large scale (i.e. all ADEs) signal detection. On the statistical 
prospect, dynamic/super control approaches estimate the frequency of a medication 
within a group of case free patients who have similar risk factors with the cases. Under 
random control, the frequency of drug is estimated within the population who has 
similar risk factors with the cases.  
1.6.3 Impact of Aim 3 
This study demonstrates the power to elucidate clinically significant high-
dimensional drug interactions from clinical records. Using two unique data sets, ADE 
case reports from the FAERS and structured electronic medical record data from the 
INPC-CDM, we observed increasing trends in myopathy risk with higher medication 
burden. As a large number of DDIs are the result of PK interactions at the level of CYP 
enzymes, we also estimated the increased exposure of 9 substrate drugs in the presence 
of 2, 3, or more inhibitors. Although we demonstrated that decreased clearance of 
drugs due to CYP inhibition is one source of the increased myopathy risk among 
polypharmacy patients, this mechanism is unable to fully explain the increased risk of 
myopathy observed in subjects taking 4 or more medications. As our computational 
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efficiency expands to allow for the evaluation of greater number of drugs using our 
MDCM model, additional pharmacokinetic and pharmacodynamic mechanisms of 
interaction will need to be considered to further account for the increased risk of ADEs 
observed in polypharmacy patients.  
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Chapter 2. The Cancer Drug Fraction of Metabolism Database 
Summary: The aim of this study is to create a database for quantifying fraction of 
metabolism (fm) of CYP450 isozymes for FDA approved cancer drugs. A reproducible 
data collection protocol was developed to extract key information including both 
substrate depletion and metabolites formation data from publicly available in vitro 
selective CYP enzyme inhibition studies. The fm was then estimated from the curated 
data. To demonstrate the utility of this database, we conduct an in vitro/in vivo drug 
interaction prediction among these 56 cancer drugs.   
2.1 Introduction 
Drugs are eliminated by excretion or metabolism after entering the human body 
(Rowland & Tozer, 2005). The majority of small molecule drugs are catalyzed by 
Cytochrome P450 (CYP) enzymes, which are located in the hepatic endoplasmic 
reticulum (Renwick, 1999; Shen et al., 1997). Many factors can alter hepatic drug 
metabolism, including genetic polymorphisms, disease and concomitant medications, 
foods etc. (Eichelbaum et al., 2006; Ereshefsky, 1996; Shah & Smith, 2015). Among these 
factors, concomitant medications are very important because of poly-pharmacy 
(Admassie et al., 2013; Fitzgerald, 2009; Hanlon et al., 1996; Rosholm et al., 1998; Sasaki 
et al., 2013). 
Many enzymatic routes of elimination, including almost all of those occurring via 
the CYP450 enzymes, can be inhibited or induced by concomitant medications. 
Particularly, when the primary metabolic pathways of a drug are inhibited or induced by 
strong inhibitors or inducers, drug and metabolite concentrations in the blood and 
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tissue can be severely affected (Vose & Ings, 2014; Yu, Ritchie, Mulgaonkar, & 
Ragueneau-Majlessi, 2014). The dramatically changed drug exposure may result in 
unwanted adverse reactions or reduced efficacy (Williams et al., 2004). A randomized, 
open-label, parallel-group study indicated that after co-administration of ketoconazole 
for 12 days, the AUC0-∞ of midazolam was about 6.56 times higher (1280 ng·h/mL vs. 
195 ng·h/mL) (Shoaf, Bricmont, & Mallikaarjun, 2012). Also, the SDMT (Symbol Digit 
Modalities Test) scores, the decrease in which represents an impairment of cognitive 
function, were reduced (-13.6 in SDMT score) by co-administration of ketoconazole and 
midazolam (Lam et al., 2003). Therefore, all these showed that midazolam and 
ketoconazole may have strong DDIs both on PD and PK. In another randomized study, 
co-administration of irbesartan with hydrochlorothiazide significantly decreased the 
hydrochlorothiazide AUC by 26.3% (1373 ng-h/ml vs. 1087 ng-h/ml). At the same time, 
the effect of irbesartan on systolic blood pressure when administered with 
hydrochlorothiazide were significantly different from those when irbesartan was 
administered alone. It was a 25% increase in Emax, and a 40% decrease in EC50, which 
suggested a synergistic blood pressure lowering effect for the combination (Hedaya & 
Helmy, 2015).  
Therefore, it is highly important to quantify the contribution of different 
metabolism pathways in order to predict drug exposure change after inhibitions (D. 
Zhang et al., 2007). The term fm, is defined as the fraction of drug metabolized by an 
enzyme. There are multiple ways that fm can be estimated through clinical 
pharmacokinetics studies or in vitro pharmacokinetics experiments. First, the 
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contributions of CYPs for a drug’s metabolism can be estimated as the change in AUC or 
clearance in the absence and presence of a co-administered selective inhibitor through 
an in vivo approach (Creighton et al., 2008; Le Coutre et al., 2008). For example, Yeung 
et al. utilized clinical drug interaction studies, in which ketoconazole was used as the 
CYP3A4 probe inhibitor, and calculated a drug’s fm in the CYP3A4 pathway using the 
following equation (Yeung et al., 2015): 
𝑓𝑚ଷ஺ସ = 1 −
𝐴𝑈𝐶௖௢௡௧௥௢௟
𝐴𝑈𝐶௜௡௛௜௕௜௧௘
 
where AUC is area under the concentration-time curve of victim drug. For example, 
cinacalcet is metabolized primarily by CYP3A4, and ketoconazole is a CYP3A4 probe 
inhibitor. The AUCinhibited/AUCcontrol is 2.03, and the fm3A4 is 0.51 using the above 
equation (Harris, Salfi, Sullivan, & Padhi, 2007). 
Second, fm can be estimated via a pharmacogenetics study where it can be 
calculated from the fold-change in exposure of a victim drug in extensive metabolizers 
(EMs) compared to poor metabolizers(PMs) (Ito et al., 2005). In Silas’s study, a large 
population of patients were studied with respect to the metabolism of metoprolol (Silas, 
McGourty, Lennard, Tucker, & Woods, 1985). After a single 200 mg oral dose of 
metoprolol，the average AUC of metoprolol in blood over the 24 hours of six PMs was 
7250 ng*ml-1*h. While in the EM population, the average AUC was much lower which 
was 1246 ng*ml-1*h. Thus, metoprolol’s fmCYP2D6 can be calculated from the formula: 
fm2D6 = 1-CLPM/CLEM=1-AUCEM/AUCPM=0.828. 
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Third, human 14C or 3H-ADME studies, which measure the concentration of the 
radiolabeled unchanged drug and its metabolites in plasma, urine and feces, is also 
regarded as a valuable approach and clinical pharmacokinetics study to estimate the 
metabolic pathways of a drug (Bohnert et al., 2016; Rodrigues et al., 2001). For example, 
[14C]faldaprevir was used for ADME study in which the formation rates of its metabolites 
by various rCYP isoforms were determined. The contribution of each cytochrome was 
determined by rates of metabolite formation after normalization by relative liver 
content of each cytochrome.  The results showed that the normalized contributions by 
CYP3A4 were 94% and 97% for two kind of metabolites (Y. Li et al., 2014). 
Several other in vitro methods have been developed to determine the 
contribution of individual cytochrome P450 isozymes in a drug’s metabolism. Substrate 
depletion in human liver microsomes (HLM) is one method that the drug is incubated 
with or without specific CYP450 selective inhibitors (Huskey et al., 1995). Comparing to 
the metabolism rate, Vmax/Km, of the substrate without any inhibitor, the percent 
inhibition of this CYP pathway by the CYP-selective chemical inhibitor reflects the 
contribution of this CYP towards the substrate’s metabolism. Ideally chemical inhibitors 
should be potent, selective and metabolically stable. Substrate depletion can also be 
incubated with individual recombinant enzymes isoforms (Z. M. Li et al., 2016). This 
approach estimates the metabolism rate, Vmax/Km, of the substrate in recombinant 
human (rh) CYP isoforms, and scales the rhCYP Vmax/Km to HLM CLint via a RAF/ISEF 
approach (Bohnert et al., 2016). Each isozymes contribution is estimated as the percent 
contribution of each CYP enzyme towards the total HLMCLint. 
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A metabolite formation study is another option. For example, after incubation, 
the mixtures of human liver microsomes and carbamazepine was analyzed by HPLC/MS. 
Rates of carbamazepine metabolites (2- and 3-hydroxycarbazepine) formation were 
determined in microsomes and then compared with typical P450 enzyme activities. Data 
were analyzed by nonlinear regression and linear transformation to estimate apparent 
PK values and enzyme models, respectively.  Then formation of 2- and 3-hydroxylated 
carbamazepine metabolites was evaluated in the presence or absence of known P450 
inhibitors (Pearce, Vakkalagadda, & Leeder, 2002). Human liver microsomes from 
high/low CYP activity donors were used to estimate the inhibition percentage of 
carbamazepine metabolites formation. Also cDNA-expressed isoforms were examined 
for the affinity of different metabolites formation. 
Recently, due to the success of the cryopreservation of human hepatocytes 
(Stephenne, Najimi, & Sokal, 2010), hepatocyte suspension model (Mao, Mohutsky, 
Harrelson, Wrighton, & Hall, 2011) becomes a new method to estimate fm. 
Physiologically, cryopreserved human hepatocyte is closer to the human hepatic 
metabolism than the other in vitro system does. Desbans (Desbans et al., 2014) used 
cryopreserved human hepatocytes from 12 donors to estimate fmCYP3A for five 
prototypical CYP3A substrates with varying degree of CYP3A-dependent in vivo 
clearance using intrinsic metabolic stability measurements in the presence and absence 
of a CYP3A probe inhibitor, ketoconazole. After hepatocytes are incubated with test 
compounds and/or the inhibitor, the intrinsic clearance was estimated from the parent 
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compound depletion profile. Then fmCYP3A was calculated from the ratio between CLint in 
absence and in presence of ketoconazole as: 
𝑓𝑚ଷ஺ = 1 −
𝐶𝐿௜௡௧ 𝑤𝑖𝑡ℎ ketoconazole
𝐶𝐿௜௡௧ 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 ketoconazole
 
 
Although there are some widely-used database for drug metabolism: a) DrugBank 
(Wishart et al., 2006), which is a comprehensive database which combines detailed drug 
(i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug 
target (i.e. sequence, structure, and pathway) information; b) Transformer (the former 
Super CYP) (Preissner et al., 2010), which integrates Cytochrome P450 enzyme 
interactions and some pharmacological information; c) DIDB (Hachad et al., 2010), 
which can evaluate the impact of DDI in the clinic by in vitro and in vivo DDI data, few 
fm data can be found. 
However, there is no database that contains fm data systemically. In this chapter, 
we present our initial effort in developing a cancer drug fm database. We focus on the 
fm data collected and estimated from in vitro inhibition studies of human liver 
microsomes, including both metabolites formation and substrate depletion studies. 
Because in vitro assessment of the metabolic rate of drugs by each of the major CYPs is 
routinely carried out in drug discovery and development, we anticipate that the fm data 
of many cancer drugs are available in the literature. The other data types (e.g. PGx test 
and clinical drug interaction PK experiment) for fm estimation will be available in the 
future. 
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2.2 Construction and Content 
The fm database was curated from published articles indexed in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed/). An overview of the data collection is available 
in Figure 2.1. In Cancer Drug Selection, 237 FDA approved cancer drugs were identified 
in DrugBank and National Cancer Institute (NCI). The next stage is the key word search, 
including cancer drug names, “cytochrome P450”, “human liver microsomes” and/or 
“metabolism”. Cancer drug generic names, their synonymous and brand names 
published in the DrugBank are included in the search. Cytochrome P450 enzyme names 
include their synonymous names in HUGO Gene Nomenclature Committee. CYP450 
enzymes and metabolism are included in the search, because we focus only on the drug 
metabolism. 
Identified PubMed abstracts were filtered. We purposely looked for whether this 
is a drug metabolism study; whether the contribution of CYP enzymes to the 
metabolisms is investigated; or whether the CYP enzyme inhibitors are discussed. If all 
these information are not reported in the abstract, this paper is then removed. If an 
abstract passes the filtering step, its full text receives further examination. In the 
Method section, substrate depletion in human liver microsomal study information 
and/or the metabolite formation study information are checked. We have searched and 
identified the following experimental information. In the metabolite formation studies, 
all incubations were performed at 37 °C; HLMs were incubated with sodium phosphate 
buffer and NADPH (usually NADP + glucose-6-phosphate dehydrogenase) before adding 
the substrates; and control samples containing no NADPH or substrates were also 
 19 
included. Well established selective inhibitors of CYP enzymes were incubated with 
substrate. Incubations are carried out for a defined time. In final stage, drug metabolites 
were evaluated using HPLC in the presence or absence known CYP enzyme selective 
inhibitors. For substrate depletion studies, pre-incubation and incubation procedures 
are the same as metabolite formation studies. However, no NADPH or substrates 
samples was needed. After being vortexed, the concentration of the remaining parent 
drugs in the supernatants was measured using the HPLC assay in the presence or 
absence selective inhibitors. If this information were not reported in the method section, 
this paper is then removed. 
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Figure 2.1 The flow chart of data collection procedure   
Cancer Drug Selection 
Abstracts Collected from the 
Keyword Search 
Abstract Filtering 
Full Text Method Checking 
Full Text Result Data Collection 
Fm Calculation 
Valadation 
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The result section is then read through carefully, including the result narrative, 
figures and tables, including their legends, or supplemental materials. We collect the 
following data from the paper for the fm calculations: The metabolites for each drug 
and/or their relative contribution of the metabolisms; the percentage of inhibitions for 
each CYP enzyme and their related CYP inhibitor (sometimes, this percentage was 
directly reported, and other times, the metabolism rates under inhibition and control 
were reported); and the substrate concentrations, and inhibitor concentrations. After 
these data are collected, fm is then calculated by metabolite formation data according 
to following steps. 
1. The metabolites from the drug by human liver microsomes are evaluated in the 
presence or absence (i.e., control sample) of known P450 isoform-selective 
inhibitors. The relative proportion of the metabolites formation in reaction 
mixtures with no inhibitor is set as 100%. If the inhibition percentage of a drug 
metabolite is not reported directly in the paper, it is calculated from the changes 
of control sample.   
2. If multiple metabolite pathways exist, the contribution of each metabolite 
pathway to the total drug metabolism will be calculated. 
3. If a CYP enzyme is inhibited by several inhibitors, the percent of inhibition for 
each inhibitor is calculated. Then, their mean value is calculated and taken as the 
inhibition percentage for this pathway. 
4. If the substrate concentration of the inhibition experiment varies in the paper, 
the percentage of inhibition at each concentration is calculated. Then, their 
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mean value is calculated and taken. 
5. The total inhibition percentage of one metabolite was normalized. The fraction of 
metabolite for the ith CYP enzyme in the jth metabolite is:  
1.  where inhibitioni refers to the percentage of inhibition for the ith enzyme. The sum of 
fmij over all metabolites is regarded as the fraction of metabolized for enzyme i. 
On the other hand, fm can be calculated through the substrate depletion data: 
1. The inhibition percentage or the remaining proportions of substrates are evaluated in 
the presence or absence (i.e., control sample) of known P450 isoform-selective 
inhibitors. And it is known that the sum of inhibition percentage of certain substrate and 
its remaining proportion equals 100%. If the inhibition percentage of a drug metabolite 
is not reported directly in the paper, it is calculated from the changes of control sample 
or the remaining percentage.   
2. If a CYP enzyme is inhibited by several inhibitors, the mean percent of inhibition for 
each inhibitor is taken as metabolite formation data. 
3. If the substrate concentration of the inhibition experiment varies, the mean 
percentage of inhibition at each concentration is taken. 
4. The metabolized fraction for the ith CYP enzyme is:  
𝑓௠ =
𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛௜
∑ 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛௜௜
 
where inhibitioni refers to the percentage of inhibition for the ith enzyme. 
i
ij
i
i
inhibitionfm percentage of pathway j
inhibition
 
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To ensure the data integrity, two curators with biology background conducted 
data curating. Dr. Sara K. Quinney who has extensive pharmacology training background 
further checked any differentially annotated abstracts. Then, the data extraction from 
the full text was carried out by those two annotators again. Among the disagreed data 
collection between these two annotators, a group review was conducted by Drs Wang, 
Quinney and Li to reach the final agreement. 
Data validation step was conducted as follows. Two sets of drugs were validated. 
In the positive set, 10 out of 57 random cancer drugs where fm data was identified are 
re-evaluated. In the negative set, 10 out of 179 random cancer drugs withoutidentified 
fm data were re-evaluated. During this validation process, two independent annotators 
went through the total fm data curating process for these twenty drugs. These two 
validation annotators have master or PhD degrees in the computational biology and/or 
biology background. Drs. Quinney and Li who have the pharmacology background 
further evaluate the concordance among these three sets of annotations. The 
consistency of fm data is reported. 
Among 237 cancer drugs, we have found fm data for 57 of them. During the 
validation, among the 10 negative cancer drugs (i.e. no fm data is identified from the 
first annotator), the other two annotators did not find their fm data either. Therefore, 
the validation overlap rate is 100% for the negative drug set. Among those 10 positive 
cancer drugs, each validation annotator manages to find fm data for 9 of them. The 
overlap rate is 90% for the positive drug set. Finally, among the overlapped positive drug 
set, the consistency of fm value are calculated. Within a 20% relative difference range, 
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60.0% and 30.0% of fm values are consistent between original annotator and validation 
annotator 1 and 2, respectively. 
Among the discordant fm values for the positive cancer drug data set, the cited 
PubMed full text papers and fm values are further evaluated by two additional 
pharmacologists. They find the original annotation has the highest accuracy in collecting 
and calculating the Fm. She is right on 85.7% of the discordant values among three 
annotators. The validation results are shown in Table 2.1. 
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  Drug 2B6 2C8 2C19 2D6 3A 2A6 2E1 2C9 1A1 1A2 
Validation annotator 1 Anastrozole 0 16.6 0 0 44.6 15.3 1.3 2.5 0 1.5 
  Dasatinib 0 0 0 0 0 0 0 0 0 0 
  Aprepitant 0 0 0 0.9 92.5 0 0 2.8 0 3.8 
  Azacitidine 0 0 0 0 0 0 58.3 0 0 41.7 
  Bortezomib 0 0 21.5 14.9 44.7 0 0 8.7 0 10.1 
  Colchicine 0 0 0 4.2 70.2 0 17.2 8.3 0 0 
  Docetaxel 0 0 0 0 45.8 0 13.2 0 0 11.5 
  Vinblastine 0 1 0 6.4 81.6 0 1 0 0 0 
  Vinorelbine 0 4.6 8.6 0.7 78.6 4.6 0 0 0 2.9 
  Irbesartan 0 24.8 0 0 3.5 46 25.6 0 0 0 
Validation annotator 2 Anastrozole 18.6 21.8 0 0 35.4 24.2 0 0 0 0 
  Dasatinib 0 0 0 0 28.2 0 0 0 22.5 0 
  Aprepitant 0 0 0 0 100 0 0 0 0 0 
  Azacitidine 0 0 0 0 0 0 0 0 0 0 
  Bortezomib 0 0 34.5 8.1 44 0 0 1.4 0 12 
  Colchicine 0 0 0 0 100 0 0 0 0 0 
  Docetaxel 0 0 0 0 100 0 0 0 0 0 
  Vinblastine 0 0 0 0 100 0 0 0 0 0 
  Vinorelbine 0 0 0 0 100 0 0 0 0 0 
  Irbesartan 0 100 0 0 0 0 0 0 0 0 
Original annotator Anastrozole 11.4 13.3 8.2 2.9 35.7 24.5 2 0 0 0 
  Dasatinib 0 0 0 0 28.2 0 0 0 22.5 0 
  Aprepitant 0 0 0 0.9 93.4 0 0 2.8 0 2.8 
  Azacitidine 0 0 0 0 0 0 58.3 0 0 41.7 
  Bortezomib 0 0 21.5 14.9 44.7 0 0 8.7 0 10.1 
  Colchicine 0 0 0 0 100 0 0 0 0 0 
  Docetaxel 0 0 0 0 67.7 0 19.6 0 0 12.7 
  Vinblastine 0 11 0 6.4 81.6 0 1 0 0 0 
  Vinorelbine 0 4.6 8.6 0.7 78.6 4.6 0 0 0 2.9 
  Irbesartan 0 24.8 0 0 3.5 46 25.6 0 0 0 
Table 2.1 The validation Results 
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2.3 Utility 
Fm database will help to predict drug interactions. These data characterize all 
the hepatic CYP450 metabolic pathways and their contributions in predicting drug 
interactions. We therefore further explore and predict the drug interactions among 
these 57 cancer drugs in the following case study. 
AUCratio (AUCR) is the key parameter to measure the drug interaction. The 
predicted AUCR is estimated as following: 
 
where is the ratio of the area under the plasma concentration-time profile of the 
substrate drug in the presence (AUCi) and absence (AUC) of the inhibitor drug;  is 
the fraction of the total hepatic metabolism mediated through a CYP enzyme (from our 
fm database),  is the unbound inhibitor concentration, is the unbound inhibition 
constant. In this chapter, equals to , where Cmax is the maximum 
concentration, and is the fraction of unbound drug in plasma. In this chapter, we 
have further identified fu, Cmax and Ki,u for 32 out of 57 cancer drugs through the 
PubMed literature review. Then, each drugs pair selected from 32 drugs are further 
evaluated twice in order to predict their interactions. Each time, one drug serves as 
substrate and the other one serves as inhibitor, and vice-versa. Following the FDA DDI 
guideline (Food & Administration, 2012) and expert experience, an AUCR >1.5 is 
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regarded as the moderate or strong DDI evidence. Based on our PBPK model based DDI 
predictions, we find 97 drug pairs with AUCR more than 1.5. After been validated in 
DrugBank, Drugs.com and PubMed, 33 pairs have at least one clear DDIs evidence 
mentioned in DrugBank or Drugs.com or in PubMed (Table 2.2). 
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Drug Pair AUCR DrugBank Drugs.com Pubmed (in vitro) 
Pubmed 
(in vivo) 
Pubmed 
(clinical) 
(vinblastine,clonidine) 38.33 
The serum concentration of 
Clonidine can be decreased when 
it is combined with Vinblastine.     
(vinorebline,clonidine) 38.33 
The serum concentration of 
Clonidine can be increased when 
it is combined with Vinorelbine.     
(etoposide,clonidine) 11.58 
The serum concentration of 
Clonidine can be increased when 
it is combined with Etoposide.     
(aprepitant,clonidine) 11.09 
The serum concentration of 
Clonidine can be increased when 
it is combined with Aprepitant.     
(sorafenib,clonidine) 7.67 
The serum concentration of 
Clonidine can be increased when 
it is combined with Sorafenib.     
(colchicine,docetaxel) 4.89 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Colchicine. 
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect. 
   
(vinblastine,docetaxel) 4.89 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Vinblastine. 
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect.  
   
(vinorebline,docetaxel) 4.89  
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect.  
   
(vincristine,clonidine) 4.26 
The serum concentration of 
Clonidine can be decreased when 
it is combined with Vincristine.     
Table 2.2 The validation results of DDI prediction based on PBPK model 
  
  
 
29 
Drug Pair AUCR DrugBank Drugs.com Pubmed (in vitro) 
Pubmed 
(in vivo) 
Pubmed 
(clinical) 
(everolimus,docetaxel) 4.16 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Everolimus. 
    
(etoposide,docetaxel) 3.94 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Etoposide. 
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect.  
   
(fenretinide,docetaxel) 3.92 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Fenretinide. 
    
(aprepitant,docetaxel) 3.89 
The serum concentration of 
Docetaxel can be increased when 
it is combined with Aprepitant. 
Coadministration with inhibitors 
of CYP450 3A4 may increase the 
plasma concentrations of 
docetaxel, which is a substrate of 
the isoenzyme.  
 
(Kaneta et al., 2014) 
(Nygren et al., 2005) 
(Kaneta et al., 2014) 
(Nygren et al., 2005) 
(sorafenib,docetaxel) 3.4 
The serum concentration of 
Docetaxel can be increased when 
it is combined with Sorafenib. 
 Coadministration with sorafenib 
may increase the plasma 
concentrations of docetaxel.   
(Awada et al., 2012) 
(Awada et al., 2012)  
(Mardjuadi et al., 
2012) 
(granisetron,docetaxel) 2.73   
(Watanabe, 
Nakajima, Nozaki, 
Hoshiai, & Noda, 
2003) 
(Watanabe et al., 
2003) (Miyata et al., 2006) 
(vincristine,docetaxel) 2.67 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Vincristine. 
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect.  
   
Table 2.2 Continued 
  
  
 
30 
Drug Pair AUCR DrugBank Drugs.com Pubmed (in vitro) 
Pubmed 
(in vivo) 
Pubmed 
(clinical) 
(irinotecan,docetaxel) 2.49 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Irinotecan. 
 (Maekawa et al., 2010)  
(Argiris, Kut, Luong, 
& Avram, 2006) 
(Engels et al., 2007) 
(ifosfamide,docetaxel) 2.46 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Palifosfamide. 
The concomitant or sequential 
administration of multiple 
antineoplastic agents may 
potentiate the risk and severity of 
additive toxicities, such as 
immunosuppression and 
myelotoxicity.  
   
(pazopanib,docetaxel) 2.17 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Pazopanib. 
Coadministration with inhibitors 
of CYP450 3A4 may increase the 
plasma concentrations of 
docetaxel, which is a substrate of 
the isoenzyme. 
   
(idarubicin,cytarabine) 2.04   
(Colburn, Giles, 
Oladovich, & Smith, 
2004) 
  
(sunitinib,clonidine) 2.02 
The serum concentration of 
Clonidine can be increased when 
it is combined with Sunitinib. 
    
(lapatinib,clonidine) 1.93 
The serum concentration of 
Clonidine can be increased when 
it is combined with Lapatinib.     
(bortezomib,clonidine) 1.77 
The metabolism of Clonidine can 
be decreased when combined 
with Bortezomib.     
(bosutinib,clonidine) 1.72 
The serum concentration of 
Clonidine can be increased when 
it is combined with Bosutinib.     
(eribulin,docetaxel) 1.71 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Eribulin. 
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect.  
   
Table 2.2 Continued 
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Drug Pair AUCR DrugBank Drugs.com Pubmed (in vitro) 
Pubmed 
(in vivo) 
Pubmed 
(clinical) 
(sunitinib,docetaxel) 1.70 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Sunitinib. 
   (Bergh et al., 2012) 
(paclitaxel,clonidine) 1.68 
The serum concentration of 
Clonidine can be increased when 
it is combined with Paclitaxel. 
    
(ixabepilone,docetaxel) 1.68 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Ixabepilone. 
 The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect 
   
(lapatinib,docetaxel) 1.65 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Lapatinib. 
 Coadministration with inhibitors 
of CYP450 3A4 may increase the 
plasma concentrations of 
docetaxel, which is a substrate of 
the isoenzyme.  
  (LoRusso et al., 2008) 
(bortezomib,docetaxel) 1.55 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Bortezomib. 
Bortezomib can cause peripheral 
neuropathy, and concurrent use 
of other agents that are also 
associated with this adverse 
effect can potentiate the risk 
and/or severity of nerve damage.  
 (Messersmith et al., 2006) 
(Messersmith et al., 
2006) 
(bosutinib,docetaxel) 1.52 
The risk or severity of adverse 
effects can be increased when 
Docetaxel is combined with 
Bosutinib. 
    
(paclitaxel,docetaxel) 1.50 
The risk or severity of adverse 
effects can be increased when 
Paclitaxel is combined with 
Docetaxel. 
The risk of peripheral neuropathy 
may be increased during 
concurrent use of two or more 
agents that are associated with 
this adverse effect 
(Maekawa et al., 
2010) 
(Watanabe et al., 
2003) 
(Royer, Monsarrat, 
Sonnier, Wright, & 
Cresteil, 1996) 
(Royer et al., 1996) 
(Esposito et al., 
1999) 
(Bahleda et al., 
2014) 
(Izquierdo et al., 
2006) 
(paroxetine,clonidine) 1.50 
The metabolism of Clonidine can 
be decreased when combined 
with Paroxetine. 
    
Table 2.2 Continued   
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2.4 Discussion 
In this cancer drug fm database, the relative contributions of CYP isozyme are 
curated and calculated from drug metabolism studied using the human liver 
microsomes. These in vitro experiments include both metabolites formation and 
substrate depletion studies from the published articles. After a number of data filtering 
and data processing steps, this database curated 57 cancer drugs with fm data for 
primary CYP450 enzymes (i.e. CYP 3A4, CYP 2D6, CYP 2C9 etc.). A predefined data 
curating protocol was established to assure data quality and data reproducibility. 
Multiple annotators were employed in the data filtering stage and the data validation 
stage. Two independent validation annotators re-evaluated the random selection from 
positive and negative set. The overlap rate is 90% and 100% for the positive and 
negative set, respectively. Among the overlapped positive drug set, the consistency of 
fm are 60.0% and 30.0% for validation annotator 1 and 2. After evaluated by two 
additional pharmacologists, the original annotation has the highest accuracy in 
collecting and calculating the fm evaluated by two additional pharmacologists. They find 
the original annotation has the highest accuracy in collecting and calculating the fm 
among three annotators. 
In our initial effort to curate fm data from the literature, we have focused on 
primarily the fm data calculate from the in vitro experiments. There are additional data, 
such as pharmacogenetics clinical PK studies and drug interaction clinical PK studies, in 
which fm can also be estimated. These fm estimates could be more accurate than the 
fm estimates from in vitro studies. 
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This database has been demonstrated successfully to predict the drug-drug 
interactions regarding several CYP isozymes. We believe that the public availability of 
this database will facilitate pharmacokinetics research.  
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Chapter 3. A Computationally Efficient Design for Electronical Health/Medical Records 
Mining 
Summary: Nested case-control design is a promising approach for detecting adverse 
drug events (ADEs) from electronical health records (HER) and electronical medical 
records (EMR) databases. Currently, computational burden is a significant challenge for 
the application of nested case-control design on EMR/HER databases, especially for 
investigating multiple ADEs. In this chapter, we propose a random control selection 
approach for nested case-control design. By relaxing the matching by case’s index time 
restriction, random control dramatically reduces the computational burden compared 
with traditional control selection approaches. By using the Observational Medical 
Outcomes Partnership gold standard and an EMR database, random control is 
demonstrated to have better performances as well.  
3.1 Introduction 
Adverse drug events (ADEs) are considered to be a significant challenge for 
current clinical practices. In the United States alone, ADEs cause approximately 125,000 
hospital admissions each year; up to 53% hospital stays prolonged; and as many as 4.6% 
of deaths (de Vries, Ramrattan, Smorenburg, Gouma, & Boermeester, 2008; Hall, 
DeFrances, Williams, Golosinskiy, & Schwartzman, 2010; Lazarou, Pomeranz, & Corey, 
1998). Though ADEs can be detected in either pre-marketing clinical trials or post-
marketing surveillances, most ADE knowledges are revealed in the post-marketing stage. 
This is because post-marketing stage allows larger population and prolonged follow up 
(Harpaz et al., 2012). Additionally, unlike pre-marketing clinical trials, drugs are 
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administered without stringent inclusion/exclusion criteria. During the past two decades, 
different types of databases have been maintained for drug safety surveillance such as 
Spontaneous Reporting System (SRS), Electronic Medical Records (EMR) and Electronic 
Health Records (EHR). SRS collects ADE reports from healthcare professionals, 
consumers, and manufacturers. EMR and EHR are administrative health databases. They 
usually contain standard medical and clinical data gathered in the provider’s offices.  
SRS and EMR/EHR analyses have gathered valuable ADE knowledges.  For a drug-
ADE pair of interest, either univariate analyses or multivariate analyses can be used for 
signal detection. Under univariate analyses, available samples are usually summarized 
by a 2-by-2 contingency table, in which contains the frequencies classified by the usage 
of the drug (yes/no) and the occurrence of the ADE (yes/no). The outcome is the 
frequency that this drug-ADE pair is co-occurred, and the expectation is the expected 
frequency of this drug-ADE pair under the assumption of no association. Univariate 
analyses are also known as disproportion analysis (DPA), as they quantify ADE signals by 
the outcome to expectation ratio (i.e. relative risk) or its variants. Frequentist DPAs 
include proportional reporting ratio (PRR) and reporting odds ratio (ROR) (Evans et al., 
2001; van Puijenbroek et al., 2002). While, the empirical Bayesian geometric mean 
(EBGM) is an empirical Bayesian DPA and the information component (IC) is a Bayesian 
DPA (Bate et al., 1998; DuMouchel, 1999). DPAs are demonstrated to have promising 
performances and are computationally efficient (Harpaz et al., 2013). However, 
confounding bias, especially confounding by co-medication, may cause biased 
disproportionality measurements of the true association. Typical multivariate analyses 
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utilize multiple logistic regression (MLR) or regulated logistic regression (RLR) models to 
adjust potential confounding variables (i.e. co-medications). Besides this advantage, 
practices of MLR/RLR are often challenged by considerable larger sample sizes of 
pharmacovigilance databases. For instance, regular computers cannot fit MLR over 
millions of samples. In a summary, DPAs are powerful tools for large scale signal 
detection, as they can be applied to multiple ADEs together (Harpaz et al., 2012). 
Multivariate analyses that models an ADE and all co-medications are preferred for 
specific hypotheses testing.  
In SRS, temporal information are omitted and each sample contains the ADE and 
drug status (Yes/No). Such a structure allows both multivariate analyses and DPAs to be 
applied directly to SRS. However, in EMR/HER database, patients are usually followed 
longitudinally with detailed temporal information about medications and phenotypes. 
As a consequence, EMR/EHR analyses typically require sophisticated epidemiology 
designs such as cohort design, self-controlled design, and nested case-control design 
(Hennessy et al., 2016). These epidemiology designs have been widely utilized for 
EMR/EHR analyses. Cohort design identifies exposure and non-exposure cohorts. ADE 
risks are estimated within each cohort, and the drug-ADE associations are estimated by 
the RR. The non-exposure cohort can be selected based on estimated propensity scores 
to ensure their similarities with the exposure cohort. For instance, Tatonetti et al. 
assumes the latent cofounders can be characterized by co-medications, and propensity 
scores are then calculated by modeling the co-medications based on such assumption 
(Tatonetti et al., 2012). For the cases and their matched controls, nested case-control 
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design uses a predefined window to examine drug exposures. For a case, usually 4 – 10 
controls are selected. The controls are usually matched with the case’s index date and 
risk factors (Schneeweiss, 2010). Additionally, they are case-free up to the case’s index 
time. Thus, such controls are also named as at risk or dynamic control. If the controls are 
restricted to be case free for the entire follow up, this type of controls is known as super 
control. Some example of application of nested case-control designs includes Brauer et 
al., La gamba et al. and Lee et al. (Brauer et al., 2014; La Gamba et al., 2017; Lee et al., 
2011). In real applications, EMR/EHR databases may contain up to millions of patients. 
Such a sample size become an obstacle for the application of epidemiology designs to 
conduct large scale (i.e. drug wide and ADE wide) ADE signal detection. For instance, as 
we mentioned above, fitting propensity score model over millions of samples cannot be 
accomplished by regular computers. Moreover, in EMR/EHR analyses, propensity scores 
will be time dependent, which further increased the computational burden. Though 
nested case-control design do not require complicated modelling, the matching process 
still computationally expensive.  
We propose a control selection approach for nested case-control design which 
will be computationally efficient for large scale ADE signal detection. Unlike the dynamic 
and super control, the proposed methods will select a pool of controls before cases are 
identified. Later, for a case, the matched controls will be patients with similar risk 
factors from the control pool. We name the proposed controls as random control, as 
both the patients and their index time are randomly selected. The key difference 
between random control and super/dynamic control is the relaxation of matching by the 
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index time condition. For super/dynamic control, at a case’s index time, all available 
samples have to be evaluated for control selection. For instance, under dynamic control, 
the samples at risk are changing over time. While, random control only need to evaluate 
the control pool for once, and avoid the time consuming evaluation processes.  In 
another word, the controls under super/dynamic control are case specific, but are not 
for random control. Additionally, random control can be applied to multiple ADEs. The 
performances of nested case-control design by using super, dynamic and random 
control will be evaluated by the Observational Medical Outcomes Partnership (OMOP) 
gold standard (Ryan et al., 2012). 
3.2 Methods 
3.2.1 Data source 
The Indiana Network for Patient Care (INPC) is a health information 
infrastructure containing medical records for over 15 million patients from five major 
hospital systems (fifteen separate hospitals) (McDonald et al., 2005). INPC-Common 
Data Model (INPC-CDM) data was derived from INPC patients between 2004 and 2015, 
following CDM Version 5.0 guideline (http://omop.org/CDM). The INPC-CDM consists of 
structured longitudinal information including medical conditions and prescription 
medications for patients. It also includes lab tests and demographics for patients. In our 
analysis, to process these complex data, medical conditions and prescription 
medications were mapped into ICD-9 codes and drugbank ID (www.drugbank.ca) with 
starting and end date. Thus, for each patient, our final data included the patient’s age, 
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gender, the starting and end date of each medical condition, and the starting and end 
date of each prescription medication. 
3.2.2 The OMOP Gold Standard 
The Observational Medical Outcomes Partnership (OMOP) gold standard was 
designed to establish a reference set for pharmacovigilance study (Ryan et al., 2012). It 
contains 399 drug-ADE pairs that were made up of 181 drugs and 4 ADEs (acute 
myocardial infarction, acute renal failure, acute liver injury, and gastrointestinal 
bleeding). These 399 drug-ADE pairs were classed as 165 true positive test cases and 
234 true negative test cases. 
In OMOP golden standard, 4 ADEs were defined by using Medical Dictionary for 
Regulatory Activities (MedDRA) (https://www.meddra.org/) Lower Level Terms (LLT). 
For our analysis, these MedDRA LLTs were mapped into ICD-9 codes. There were total 
44, 6, 16, and 12 ICD-9 codes for acute myocardial infarction, acute renal failure, acute 
liver injury, and gastrointestinal bleeding respectively. 
3.2.3 Study Designs 
We aim for evaluating the performances of super, dynamic and random controls 
under a nested case-control design. The design is similar as existing EMR data analysis 
(Duke et al., 2012; Han et al., 2015; P. Zhang et al., 2015). Under the nested case-control 
design, we select 4 controls for each case. Each case and control will have an index time. 
At each index time, we examine the medications up to 30 days prior to the index time 
(one month drug window). Naturally, for a drug and an ADE, the data can be 
summarized as Table 3.1. 
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3.2.3.1 Case selection 
For each ADE, two types of new case events were defined. The first type was the 
first case event where the first ADE occurred. The second case event type included any 
follow-up ADE event whose corresponding drug exposure was more than 6 months after 
the previous ADE event. In other words, the second type of new ADE case event 
required a “washout” period (i.e., no drug exposure) of more than 6 months. Summary 
statistics for each ADE are shown in Table 3.2. We identified total 204,780, 281,461, 
261,874, and 221,330 ADE case events for acute myocardial infarction, acute renal 
failure, acute liver injury, and gastrointestinal bleeding with occurred percentage of 
3.77%, 5.18%, 4.82%, and 4.07% respectively. 
After the cases were identified, 𝑎 and 𝑏 in Table 3.1 can be determined for a 
selected drug. While, under different control selection approaches 𝑐 and 𝑑 are different.   
3.2.3.2 No Control Selection (All patients) 
We first conduct an analysis by using all patients without a control selection 
approach. Without control selection, 𝑐 was the frequency of patients who experienced 
the ADE but unexposed to the drug in the entire follow up; 𝑑 was the frequency of 
patients who neither experienced the ADE nor exposed to the drug in the entire follow 
up. These analyses will be served as reference for the following control selection 
approaches. 
3.2.3.3 Super Control and Dynamic control Selection 
The controls were matched with case’s index time, age and gender. Additionally, 
we restricted the controls and the case to have equal number of medications within the 
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one month drug window. At each case’s index time, control patients were selected by 
these rules. Further, the dynamic controls were sampled from patients who were case 
free at the index time. On the other hand, the super controls were selected from 
patients who were case-free for their entire follow up. 
3.2.3.4 Random control Selection 
For random control selection, a control pool was randomly selected from all 
patients first. Similarly, we selected a random index time for each control patient in the 
pool. For each case, matched control were patients from the control pool with same age, 
gender and number of medications. In our analysis, we selected 1 million patients to 
from the control pool.  
3.2.4 Comparison analysis  
By using OMOP gold standard, DPAs and multivariate analyses were shown to 
have comparable performances (Harpaz et al., 2013). Hence, in this study, we selected 2 
frequentist and 1 Bayesian DPAs for evaluation. They were PRR, ROR and IC (Bate et al., 
1998; Evans et al., 2001; van Puijenbroek et al., 2002). Start from Table 3.1, the PRR, 
ROR and IC were given in Table 3.3. 
Normal approximation and delta method can be used to compute the variances 
of PRR, ROR and IC. The lower bound of 95% confidence intervals, PRR_025, ROR_025 
and IC_025, will be used for evaluation as well. For this DPAs, common threshold, 1 for 
PRR, PRR_025, ROR and ROR_025; and 0 for IC and IC_025 were adopted for evaluation.  
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 Case Control Total 
Drug  𝑎 𝑏 𝑎 + 𝑏 
No Drug 𝑐 𝑑 𝑐 + 𝑑 
Total 𝑎 + 𝑐 𝑏 + 𝑑 𝑎 + 𝑏 + 𝑐 + 𝑑 
Table 3.1 2-by-2 contingency table for a drug-ADE pair 
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Adverse Event Case Event  Percentage Case Patients 
Myocardial Infarction 204,780 3.77% 137,439 
GI Bleed 281,461 5.18% 235,056 
Liver Injury 261,874 4.82% 200,956 
Acute Renal Failure 221,330 4.07% 165,469 
Table 3.2 Summary statistics for each ADE (each patient can have multiple new case events) 
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DPA Formula Description 
PRR (Evans et al., 2001) 
𝑎
(𝑎 + 𝑏)
𝑐
(𝑐 + 𝑑)
൘  
PRR measures the ratio of P(ADE|Drug) 
over P(ADE|No Drug). 
 
ROR (van Puijenbroek et al., 2002) 
𝑎
𝑏
𝑐
𝑑
ൗ  
ROR measures the ratio of ୔(୅ୈ୉|ୈ୰୳୥)
୔(୒୭ ୅ୈ୉|ୈ୰୳୥)
 
over ୔(୅ୈ୉|୒୭ ୈ୰୳୥)
୔(୒୭ ୅ୈ୉|୒୭ ୈ୰୳୥)
 
 
IC (Bate et al., 1998) logଶ ቎
𝑎 + 1
(𝑎 + 𝑐) × (𝑎 + 𝑏)
𝑎 + 𝑏 + 𝑐 + 𝑑 + 1
቏ 
IC is the log 2 transformed outcome to 
expectation ratio ቀ ୔(୅ୈ୉ &ୈ୰୳୥)
୔(୅ୈ୉)×୔(ୈ୰୳୥)
ቁ. By 
adding 1 on both the numerator and the 
denominator, infrequent drug-ADE pairs 
will have penalized IC values. 
Table 3.3 PRR, ROR and IC 
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3.3 Results 
3.3.1 Performance evaluation under common signal detection rules 
The performances including specificity, sensitivity, precision, recall and F-score 
under common signal detection rules are shown in Table 3.4. Among all four control 
selection methods, random control approach has significant better F-scores (0.42-0.46) 
than the other three methods (0.21-0.30). Moreover, random control approach leads to 
better recall (0.36-0.41) compared to the other three approaches (0.12-0.23). All 
patients approach generates the best precision (0.79), followed by random control 
method (0.36-0.41), and dynamic control and super control methods have equally worst 
precision (0.42-0.45).  
3.3.2 Area under the receiver operating characteristic curve (AUC) analysis 
To further explore the properties of each control selection approach, we conduct 
AUC analysis. The AUCs are shown in Figure 3.1. After classification, there is no 
significant difference between dynamic control (AUC: 0.38-0.57) and super control (AUC: 
0.36-0.58). All patients approach has the best overall AUC scores (0.59-0.62), followed 
by random control approach (0.57-0.60), and dynamic control and super control 
approaches have equally worst precision (0.48-0.54) in all three evaluation method (PRR, 
ROR, and IC). In sub-category phenotypes, all patients approach achieves the best AUC 
score (0.71-0.73 and 0.59-0.61) in acute liver injury and acute renal failure, but not 
preforms well in acute myocardial infarction and gastrointestinal bleeding phenotypes 
with AUC (0.47-0.51 and 0.43-0.50). Random control approach is consistently generated 
good scores across all four phenotypes (0.46-0.62). In acute myocardial infarction, acute 
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liver injury and acute renal failure phenotypes, AUC (0.49-0.62) is comparable to all 
patients approach (0.47-0.73), but significant better than dynamic control and super 
control approach (0.35-0.51). In gastrointestinal bleeding phenotype, random control 
approach is equally good as dynamic control and super control methods with AUC (0.46-
0.56) and (4.48-0.58) respectively.  
Further, for all four ADEs, the AUC curves for random control approach and all 
patients approach are shown in Figure 3.2. Generally, two methods have comparable 
curves. While, random control have better true positive rates under lower false positive 
rates for all three matrices.  
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Method Design Specificity Sensitivity Precision Recall F-score 
PRR025 > 1 
Dynamic Control 0.8058 0.1938 0.4366 0.1938 0.2684 
Super Control 0.7961 0.1938 0.4247 0.1938 0.2661 
Random Control 0.7330 0.3625 0.5133 0.3625 0.4249 
All Patients 0.9757 0.1188 0.7917 0.1188 0.2065 
 
ROR025 > 1 
Dynamic Control 0.7864 0.2250 0.4500 0.2250 0.3000 
Super Control 0.7913 0.2125 0.4416 0.2125 0.2869 
Random Control 0.7136 0.4062 0.5242 0.4062 0.4577 
All Patients 0.9757 0.1188 0.7917 0.1188 0.2065 
 
IC025 > 0 
Dynamic Control 0.8058 0.1938 0.4366 0.1938 0.2684 
Super Control 0.8010 0.1938 0.4306 0.1938 0.2672 
Random Control 0.7330 0.3625 0.5133 0.3625 0.4249 
All Patients 0.9757 0.1188 0.7917 0.1188 0.2065 
Table 3.4 Performances of different control selection approaches 
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Figure 3.1 AUC values for four control selection strategies 
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Figure 3.2 AUC curves for all patients analysis and random control 
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3.4 Conclusion and Discussion 
In this study, we propose a random control approach based nested case-control 
design for EMR/EHR analyses. For a case, random controls are matched patients who 
have same risk factors as the case. While, compared with the dynamic/super control 
selection approach, random control selection relaxes the matching by the cases’ index 
time restriction, which is the most computational expensive step. Under the matching 
by the cases’ index time restriction, the risk factors for all patients will be examined at 
each distinct index time. Given the sample size and the amount of distinct case index 
times of EMR/HER data, such matching process generates a considerable computational 
burden. Moreover, for investigating multiple ADEs, the dynamic/super controls have to 
be different, which further increase the computational burden. For random controls, 
patients will be randomly selected to from a control pool, and index times are randomly 
selected as well. Hence, the risk factor evaluation is only limited to the control pool at 
the index times. Additionally, the control pools can be used for multiple ADEs. As a 
consequence, random control selection is efficient for large scale (i.e. all ADEs) signal 
detection. On the statistical prospect, dynamic/super control approaches estimate the 
frequency of a medication within a group of case free patients who have similar risk 
factors with the cases. Under random control, the frequency of drug is estimated within 
the population who has similar risk factors with the cases.  
Additionally, we evaluate the performances of random control and other control 
selection approaches by using the OMOP gold standard and the INPC-CDM data. For 
each of the 399 drug-ADE pairs in the OMOP gold standard, samples in our data are 
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summarized into a 2-by-2 contingency table (Table 3.1). Six disproportionality 
measurements of drug-ADE association that generate from three ADE signal detection 
methods (2 frequentists and 1 Bayesian) are calculated. Finally, we compute the area 
under ROC curve (AUC) values by using these disproportionality measurements. We 
observe the random control (AUC: 0.572 – 0.597) and all patients analysis (AUC: 0.595 – 
0.619) have modest well AUCs. While, the dynamic controls (AUC: 0.492 -0.539) and 
super controls (AUC: 0.482 – 0.538) have less powerful detection capability.  
The goal of this study is to find a computational efficient study design for large 
scale EMR/EHR analysis. Through AUC analyses, the random control selection has a 
modest well detection capability. Its average AUC value is only less than the best 
average AUC value. The modest detection capability that we observed in this study 
coincides with a few other studies, which aimed to evaluate the performance of 
different ADE signal detection methods. For instance, Ryan et al. initially evaluated the 
signal detection methods on multiple EMR/EHR databases (Ryan et al., 2012).  Their 
analysis is based on the OMOP gold standard. Results shown that case crossover design 
had AUC = 0.66 and case-control design had AUC = 0.62. Liu et al. perform an evaluation 
by using an EMR data from Vanderbilt University Medical Center and another gold 
standard (Liu et al., 2013). In their analysis, the evaluation is based on F-score. Results 
shown that PRR and ROR have F-score = 0.62, and IC has F-score = 0.60. In order to 
achieve better performance, multivariate methods may be used, as they are 
demonstrated to have better performances than DPAs. As we solely focused on study 
design, only DPAs are used for evaluation.  
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Chapter 4. Translational high-dimensional drug Interaction discovery and validation 
using health record databases and pharmacokinetics models 
Summary: Polypharmacy increases the risk of drug-drug interactions (DDI’s). Combining 
epidemiological studies with pharmacokinetic modeling, we detected and evaluated 
high-dimensional DDI’s among thirty frequent drugs. Multi-drug combinations that 
increased risk of myopathy were identified in the FDA Adverse Event Reporting System 
(FAERS) and electronic medical record (EMR) databases by a mixture drug-count 
response model. CYP450 inhibition was estimated among the 30 drugs in the presence 
of 1 to 4 inhibitors using in vitro in vivo extrapolation. Twenty-eight 3-way and 43 4-way 
DDI’s had significant myopathy risk in both databases and predicted increases in the 
area under the concentration time curve ratio (AUCR) >2-fold.  The HD-DDI of 
omeprazole, fluconazole and clonidine was associated with a 6.41-fold (FAERS) and 
18.46-fold (EMR) increase risk of myopathy (LFDR<0.005); the AUCR of omeprazole in 
this combination was 9.35.The combination of health record informatics and 
pharmacokinetic modeling is a powerful translational approach to detect high-
dimensional DDI’s.  
4.1 Introduction 
Drug-drug interactions (DDIs) are a common cause of adverse drug events (ADE) 
(Hajjar et al., 2007; U.S. Department of Health and Human Services; L. Zhang et al., 
2009). In the United States alone, each year an estimated 195,000 hospitalizations and 
74,000 emergency room visits are the result of DDIs. National Health and Nutrition 
Examination Survey data published in 2010 (Gu et al., 2010) showed that the number of 
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patients using two or more prescription drugs increased from 25.4% to 31.2% in ten 
years. In particular, more than 64% of elderly individuals took three or more 
prescription drugs, and 37% took five or more prescription drugs (Gu et al., 2010). In the 
FDA Adverse Event Reporting System (FAERS) data, 35% of reports include three or 
more prescription drugs, and 20% reports have five or more prescription drugs. 
In order to evaluate clinical effects and molecular mechanisms of DDIs, clinical 
pharmacokinetic (PK) studies, pharmaco-epidemiologic studies, and in vitro PK 
experiments have been routinely utilized. One salient example is that of breast cancer 
hormonal therapy, tamoxifen. The formation of its active metabolite, endoxifen, was 
inhibited by concomitant selective serotonin reuptake inhibitor paroxetine in a clinical 
pharmacokinetics study (Stearns et al., 2003). In vitro metabolism studies revealed that 
this is due to paroxetine’s strong inhibition of the tamoxifen bio-transformation to 
endoxifen via the CYP2D6 pathway (Desta et al., 2004). In a follow-up pharmacogenetic 
study, breast cancer patients with CYP2D6 loss function variants have a higher risk of 
disease relapse and a lower incidence of hot flush (Goetz et al., 2005). The clinical 
consequence of treating breast cancer and depression using tamoxifen and SSRIs was 
reviewed (Henry et al., 2008), and a call made for further investigation. Another 
example is the sedation agent midazolam. Co-administration of midazolam and 
ergosterol synthesis inhibitor ketoconazole has been identified to reduced subjects’ 
cognitive function (Lam et al., 2003). In clinical PK and in vitro experiments, midazolam 
metabolism was inhibited by ketoconazole through the CYP3A pathway (Gascon & 
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Dayer, 1991; Gorski et al., 1994), leading to increased midazolam exposure (Olkkola et 
al., 1994). 
These examples clearly demonstrate that the translational significance of drug 
interaction studies relies on both clinical and molecular pharmacology evidence. As 
described by Hennessy and Flockhart (Hennessy & Flockhart, 2012), an integrated 
informatics, epidemiology, and pharmacology approach has the potential to accelerate 
the translational drug interaction studies. Pioneered by Tatonetti et al. (Tatonetti et al., 
2012), FAERS and electronic medical records were utilized to generate and validate 
drug-ADE and drug-drug-ADE associations. In a follow-up study, Lorberbaum et al. 
demonstrated that patients co-administrated ceftriaxone and lansoprazole were 1.4 
times as likely to have a prolong QT prolongation than the administrated single drug in 
both EMR and FAERS data. Further validation showed that ceftriaxone/lansoprazole 
drug interaction was due to hERG channel blocker in a patch-clamp experiment system 
(Lorberbaum et al., 2016). Duke et al. proposed a text mining strategy for DDI molecular 
pharmacology evidence discovery from the public literature (Duke et al., 2012), which 
discovered 13,197 potential DDIs. In the follow-up in vitro study, Han et al. validated the 
loratadine-simvastatin myotoxicity interaction, and its increased myopathy risk in both 
EMR and FAERS databases (Han et al., 2015). Similarly, Schelleman et al. examined the 
increased risk of hypoglycaemia with co-administration of fibrates and statins in 
sulfonylurea users in a pharmaco-epidemiology study (Schelleman et al., 2014). This DDI 
was further evaluated in an in vitro in vivo extrapolation (IVIVE) pharmacokinetic model.  
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High dimensional drug interactions (HDDIs), i.e. DDIs with three or more drugs, 
have not yet been broadly investigated. There are a few examples of clinical PK studies, 
in vitro PK experiments, and IVIVE PK models that evaluate interactions among 3 or 
more drugs. Co-administration of gemfibrozil and itraconazole were shown to increase 
repaglinide plasma exposure to a greater extent than either one alone (Niemi, Backman, 
Neuvonen, & Neuvonen, 2003). Zhang et al. found an additive PK model, including 
mechanism-based and competitive components, best described the in vitro inhibition of 
midazolam metabolism by erythromycin, diltiazem and their metabolites (X. Zhang, 
Jones, & Hall, 2009). Through IVIVE, this model was confirmed in vivo in mice (X. Zhang, 
Quinney, Gorski, Jones, & Hall, 2009). On the other hand, to our knowledge, there are 
no studies of three way drug interactions using pharmaco-epidemiology studies. 
Proportional reporting ratio (PRR) (Evans et al., 2001), the reporting odds ratio (ROR) 
(van Puijenbroek et al., 2002), the information component (IC) (Bate et al., 1998), and 
the empirical Bayes geometric mean (EBGM) (DuMouchel, 1999) have been proposed 
for detection of drug-ADE signals. However, these methods are focused on ADE 
detection for single drugs, not drug combination. To overcome this limitation, we have 
recently developed a new method, a mixture drug-count response model (MDCM). This 
model focuses on detecting high dimensional drug interactions, and characterizes the 
drug-count response relationship between the number of co-administered drugs and an 
ADE. We have successfully demonstrated its statistical and computational performance 
in a recent publication (P. Zhang et al., 2015). 
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In this chapter, we will use this newly developed MDCM to detect HDDIs that 
lead to increased risk of myopathy in two independent databases: Indiana Network of 
Patient Care - CDM (INPC-CDM) electronic medical record and FAERS. Using in vitro 
cytochrome P450 (CYP) inhibition data and mechanistic static in vitro in vivo DDI 
predictions, we evaluate the potential pharmacological mechanisms of these HDDIs. 
4.2 Materials and Methods 
4.2.1 Indiana Network of Patient Care (INPC) Electronic Medical Record 
INPC-CDM data was derived from INPC patients between 2004 and 2015, 
following CDM Version 5.0 guideline (http://omop.org/CDM). The INPC-CDM consists of 
structured data detailing medical conditions, medications, and lab tests of patients. 
Using this data set, we have identified myopathy patients, as defined in our previous 
paper (Duke et al., Table S6 (Duke et al., 2012)). The myopathy case definition contains 
both severe symptoms, such as rhabdomyolysis, and mild symptoms, such as muscle 
weakness. The myopathy cases include the first myopathy event recorded for a patient 
and cases in which no other myopathy event occurred within the past 6 months. For 
each case, ten controls were selected from records within the same time-frame (anchor 
time-matched) and matching demographic criteria. These controls did not have any 
myopathy events recorded in the INPC-CDM data set. Under each anchor time in both 
cases and matched controls, a one-month drug exposure window was generated. Drugs 
were coded as present if their prescription time periods overlapped with the drug 
exposure window. Drug names were normalized to their DrugBank IDs. The INPC-CDM 
data set has 450,673 cases and 4,506,730 controls. This case/control design for the 
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myopathy using the INPC-CDM database was similar to that used in our previous 
publications (Fahmi et al., 2008; Han et al., 2015; P. Zhang et al., 2015). 
4.2.2 FDA Adverse Event Reporting System (FAERS) 
In FAERS, myopathy cases were similarly identified using the same terms we 
used in the INPC-CDM (Table 4.1). There were 136,791 myopathy cases, and 3,969,842 
controls identified in the FAERS. The drug names were mapped to their DrugBank IDs. 
4.2.3 Drug Selection Criteria and Data Curation 
- Only FDA-approved drugs included 
- Selected by frequency >0.5% in both INPC and FAERS databases 
- Myopathy risk identified in SIDER 
- Limited to 30 drugs due to computational expense of MDCM 
Pharmacokinetic parameters required for in vitro in vivo extrapolation of AUCR 
(Cmax, fu, fm, Km, Vmax, Ki) were curated from Goodman and Gilman (Goodman, Gilman, 
Brunton, Lazo, & Parker, 2006) or published literature identified in PubMed. Cmax 
obtained from literature review (Goodman et al., 2006) was used as the inhibitor 
concentration [𝐼]. This conservative approach to estimate maximal inhibition has been 
used by others (Lu, Miwa, Prakash, Gan, & Balani, 2007). If a pharmacokinetics 
parameter was reported in multiple sources, the sample mean was used.  
The fm data was curated from several different types of published studies. Most 
of the fm data were estimated from substrate depletion studies in human liver 
microsomes, in which the substrate is incubated with or without CYP-selective inhibitors 
(Huskey et al., 1995). The percentage inhibition caused by the CYP-selective inhibitor 
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reflects the fm of drug for this CYP. The fm can also be estimated through in vivo 
pharmacokinetic studies comparing the AUC or clearance of a substrate in the presence 
and absence of a CYP-selective inhibitor (Creighton et al., 2008) or in a pharmacogenetic 
PK study where it can be calculated from the fold-change in exposure of a victim drug in 
extensive metabolizers compared to poor metabolizers (Ito et al., 2005; P. Zhang et al., 
2015). 
4.2.4 A Mixture Drug-Count-Response Model for the High-Dimensional Drug Effect on 
Myopathy 
In 2015, our group developed a mixture drug-count-response model (MDCM) for 
identifying high-dimensional drug interaction-induced ADEs (P. Zhang et al., 2015). In 
the MDCM, i is denoted as the number of drugs for i-way drug combinations; j is the jth 
i-way drug combinations; 𝑛௜௝ is the total number of patients taking jth i-way drug 
combination; and 𝑦௜௝  is the number of cases among those 𝑛௜௝ patients. The parameter 𝜋 
represents the proportion of drug combinations that follow the drug-count-response 
model. The probability distribution of 𝑦௜௝  is defined as the following mixture model  
𝑃(𝑦௜௝) = (1 − 𝜋 )𝐵𝑖𝑛൫𝑛௜௝, 𝑦௜௝ , 𝑃௖௢௡௦௧൯ + 𝜋 𝐵𝑖𝑛൫𝑛௜௝, 𝑦௜௝ , 𝑃௖௢௨௡௧൯            (Eq. 1) 
where 𝑃௖௢௡௦௧ and 𝑃௖௢௨௡௧ represent a constant ADE risk probability and a drug-count-
response ADE risk probability respectively: 
𝑃௖௢௡௦௧ =
ୡ×ୣ୶୮ (ఉబ)
ଵାୣ୶୮ (ఉబ)
, 𝑃௖௢௡௦௧  =
ୡ×ୣ୶୮ (ఉబାఉభ(௜ିଵ))
ଵାୣ୶୮ (ఉబାఉభ(௜ିଵ))
.  
After applying MDCM to both FAERS and INPC-CDM data, a local false discovery rate 
(LFDR) is calculated for each drug combination. A LFDR demonstrates the significance of 
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a drug combination that follows the drug-count-response model. Then, all the drug 
combinations are ranked based on the LFDR accordingly. 
𝐿𝐹𝐷𝑅 =
(ଵିగ)஻௜௡൫௡೔ೕ,௬೔ೕ,௉೎೚೙ೞ೟൯
(ଵିగ)஻௜௡൫௡೔ೕ,௬೔ೕ,௉೎೚೙ೞ೟൯ାగ஻௜௡൫௡೔ೕ,௬೔ೕ,௉೎೚೙ೞ೟൯
                                (Eq. 2) 
This MDCM allows different drug combinations to share the same risk probabilities, 
either a constant risk or a drug-count-response risk. This strategy overcomes the small 
sample size in each high dimensional drug combination. In this chapter, we evaluate the 
dimension of the drugs taken from single drug to 5 co-administered drugs.  
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INPC – CDM FAERS 
Disorder of skeletal muscle (Myopathy) Myopathy 
Muscle pain (Myalgia and myositis) Myositis 
 Myalgia 
Muscle, ligament and fascia disorders 
(Rhabdomyolysis) 
Rhabdomyolysis 
Muscle weakness Muscular weakness 
Polymyositis Polymyositis 
Myoglobinuria Myoglobinuria 
 Muscle spasms 
 Muscle injury 
 Muscle fatigue 
Table 4.1 Myopathy phenotype definition 
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4.2.5 Sensitivity Data Analysis 
Overlapping and mutually validated significant (LFDR < 0.05) high dimensional 
drug combinations between FAERS and INPC-CDM data were further evaluated. In the 
follow-up sensitivity analyses, a sequential logistic regression was conducted to 
compare myopathy risk between any two adjacent dimensions of drug combinations, 
for example 1-way vs 2-way, 2-way vs 3-way, etc. The logistic regression model included 
the demographic, and the number of other co-medications as covariates to adjust for 
the confounding effects.  
4.2.6 High Dimensional Drug Interaction In-Vitro to In-Vivo Extrapolation (IVIVE)  
A substrate’s clearance (CLtotal) is composed of hepatic clearance (CLH) and renal 
clearance (CLR), 𝐶𝑙௧௢௧௔௟ = 𝐶𝑙ு + 𝐶𝑙ோ. The ratio of area of under the concentration-time 
curve in the presence and absence of inhibitor (AUCR) is defined in (Eq 3), where C𝑙ு
ᇱis 
the hepatic clearance of the substrate drug after inhibition (Ito, Brown, & Houston, 
2004). 
                                                        AUCR = ஺௎஼
ᇲ
஺௎஼
= େ௟೟೚೟ೌ೗
େ௟೟೚೟ೌ೗
ᇲ =
େ௟ಹାେ௟ೃ
େ௟ಹᇲାେ௟ೃ
                           (Eq. 3)                              
Let the fraction of the renal clearance (𝑓௘) =
େ௟ೃ
େ௟ಹାେ௟ೃ
 , and C𝑙ோ = C𝑙ு ൭
𝑓௘
1 − 𝑓௘ൗ ൱, and 
the AUCR can be further defined as  
AUCR =
1
(1 − 𝑓௘)
C𝑙ு
ᇱ
C𝑙ு
+ 𝑓௘
 
For high clearance drugs in which CLint approaches hepatic blood flow, C𝑙ு is limited by 
hepatic blood flow rate, and significant hepatic inhibition is unlikely. For the low 
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clearance drugs, ஼௟ಹ
ᇲ
஼௟ಹ
= ௙ೠ஼௟೔೙೟
ᇲ
௙ೠ஼௟೔೙೟
= ஼௟೔೙೟
ᇲ
஼௟೔೙೟
= ∑ 𝑓𝑚௜
஼௟೔೙೟,೔ᇲ
஼௟೔೙೟,೔
, where 𝑓𝑚௜  is the fraction of 
metabolism by CYP enzyme (i) , and ∑ 𝑓𝑚௜௡௜ୀଵ = 1 where n is the number of metabolism 
routes. 
When there is only one inhibitor and one metabolizing enzyme, Ito et al. (Ito et 
al., 2004; Ito et al., 2005) showed that the change in clearance in the presence of a DDI 
can be predicted as ஼௟೔೙೟,೔
ᇲ
஼௟೔೙೟,೔
= ଵ
ଵା[಺]ೖ೔
, where[𝐼] is fraction unbound concentration of the 
inhibitor and Ki is the competitive inhibition constant. If there are inhibitors on the same 
enzyme, the inhibitors’ effects are assumed to fit an additive model (Rostami-Hodjegan 
& Tucker, 2007). The AUCR for inhibition of a single enzyme then becomes 
𝐴𝑈𝐶𝑅 =  
𝐶𝑙௜௡௧,௜
ᇱ
𝐶𝑙௜௡௧,௜
=
1
1 + ቆ∑
ൣ𝐼௝൧
𝑘𝑖௝
௃
௝ୀଵ ቇ
 
When considering multiple inhibitors and multiple enzyme pathways, the AUCR is 
predicted by equation 4 (Lu et al., 2007): 
𝐴𝑈𝐶𝑅 = ଵ
(ଵି௙೐) ∑ ௙௠೔×
భ
భశቌ∑
ቂ಺ೕቃ
ೖ೔ೕ
಻
ೕసభ ቍ
೙
೔సభ  ା ௙೐
                                    (Eq. 4) 
We used this method to predict the AUCR for each substrate drug in the presence of 1- 
to 4- inhibitors. 
4.3 Results 
4.3.1 Drug Selections 
As our MDCM is computationally expensive, we limited this analysis to top 30 
drugs. After normalizing drug names by their DrugBank IDs, 1,238 and 1,716 FDA 
approved drugs were identified in the INPC-CDM and FAERS datasets. Of these, after 
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selecting drugs 268 and 172 drugs in INPC-CDM and FAERS, respectively, had a relative 
frequency ≥0.5%, with 119 drugs overlapping both databases. Among these 119 drugs, 
95 have reported myopathy risk according to SIDER (http://sideeffects.embl.de/). We 
curated the in vitro pharmacokinetic data for these 119 drugs to determine their 
potential to interact via CYP450 inhibition. Nine drugs had reported fraction metabolism 
(fm) by human CYP450 enzymes. These drugs were evaluated as substrates for the 
prediction of area under the concentration-time curve ratio in the presence to absence 
of inhibitor (AUCR). Published competitive inhibition (ki) values for at least one CYP450 
enzyme were available for 64 of the drugs. The top 23 drugs with inhibition ranked by 
௙ೠ×஼೘ೌೣ
௞೔
 were selected as inhibitors (Figure 4.1). 
4.3.2 INPC-CDM and FAERS Show Strikingly Different Drug-Count Myopathy Response 
Mixture Models 
Under the MDCM, each drug combination has a probability of being assigned to 
either a drug-count myopathy response model or a constant myopathy risk model. The 
drug-count response model and constant model share the same myopathy risk when 
subjects take only one drug. The drug-count myopathy response model captures the 
overall trend of the nonlinear relationship between the number of co-administered 
drugs and myopathy risk. It also characterizes a constant myopathy risk and the 
maximum myopathy risk as the number of co-administered drugs increases. Strikingly, 
the drug-count response model demonstrated very different trends between drug 
combinations and myopathy risk in INPC-CDM and FAERS databases. INPC-CDM had 
constant myopathy risk of 0.42, and maximum risk of 0.74; while FAERS data shows 
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constant risk of 0.07 and a maximum risk of 1.0 (Figure 4.2). In the INPC-CDM, the 
maximum myopathy risk occurs when the four drugs are co-administered. However, in 
the FAERS, the myopathy risk continues to increase beyond 5-drug combinations. 
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Figure 4.1 Drugs selection flow chart 
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Figure 4.2 Mixture dose-response model curve for both INPC and FAERS data. Red dash line is the baseline risk estimated; Blue dash 
line is maximum risk estimated. 
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4.3.3 Overlapping Drug Combinations in INPC-CDM and FAERS 
The drug-count-response mixture model generates a local false discovery rate 
(LFDR) statistic that allows us to differentiate drug combinations that are more likely to 
follow the drug-response myopathy risk model than the constant risk model. Figure 4.3 
shows the percentage of overlapping drug combinations that are shared between two 
databases, with a LFDR of 0.05. We see strong and consistent evidence of increased 
myopathy risk with an overlap of 37-40% of 2-way to 5-way drug combinations shown to 
increase myopathy risk in both databases.   
4.3.4 The Overall Trend of High Dimensional Drug Interactions in Pharmacokinetics 
Predicted by IVIVE 
One common mechanism of drug-drug interaction occurs through inhibition of 
drug metabolism.  In order to assess whether the potential DDIs identified by pharmaco-
epidemiology evidence are due to pharmacokinetic drug interactions, we used IVIVE to 
evaluate the change in drug exposure between a drug administered alone and co-
administered with 2-, 3-, or more drugs. In the IVIVE prediction, CYP substrates and CYP 
inhibitors are differentially defined. Among our 30 selected drugs, nine are CYP 
substrates with curated fm, fe, and fu data from the literature. We also obtained the ki, fu, 
and Cmax for 23 drugs identified as CYP inhibitors. These data were combined through 
IVIVE to predict the area under the concentration time curve ratio (AUCR) for 156 two-
way, 1302 three-way, 6971 four-way, and 26901 five-way drug interaction combinations 
(Figure 4.4). When we look at all the AUCR data under different dimensions of drug 
interactions, their medians, 75th percentiles, and the maximum AUCRs all reach a 
maximum plateau with the co-administration of 3 drugs. 
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4.3.5 Significant Three-way Drug Interactions and Their Sensitivity Analyses  
Among the 9 substrates and 23 inhibitors, 28 three-way drug interactions have a 
predicted AUCR >2 and a LFDR from the MDCM model < 0.05. We hypothesized that 
among these drugs, the risk of myopathy would increase as the number of co-occurring 
drugs increased. Therefore, for each 3-drug combination we evaluated myopathy risk 
between individuals taking 1 drug vs any 2-drug combination, and between 2-drug and 
3-drug combinations. One drug-triplet showed a strong increasing trend in myopathy 
risk: omeprazole, clonidine, and fluconazole (Figure 4.5) after adjusting for the number 
of additional co-medications, age, and gender. In the FAERS data set, taking any two of 
these three drugs together increased the risk of myopathy by 1.88-fold compared to 
taking any of the drugs alone (p = 0.012). Taking the 3-drug combination of omeprazole, 
clonidine and fluconazole increased the risk of myopathy by 5.01-fold compared to the 
2-drug combinations (p = 0.000012). In the INPC-CDM, taking any two of these drugs 
concurrently increased the risk of myopathy by 1.75-fold (p=7.8E-13) and taking all 
three together increased the risk by 4.18-fold (p=0.0069) compared to taking one drug 
and two drugs, respectively. Similar comparisons of 2- and 3-drug combinations to 1- 
and 2 drug combinations for the other 27 drug triplets examined did not reveal 
significantly increased myopathy risk in both data sets for other drug combinations 
(Table 4.2). 
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Figure 4.3 Overlapped drug combination between INPC and FAERS dataset. * LFDR < 
0.05 
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Figure 4.4 Simulated AUCR of 2-way to 5-way drugs combination. Only AUCR>=1.25 are 
reported here.  
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Figure 4.5 Group-wise odds ratio analysis; OMZ is omeprazole or esomeprazole; CLN is clonidine; FLU is fluconazole 
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Drugs LFDR AUCR INPC-CDM FAERS 
Substrate Inhibitor 1 Inhibitor 2 INPC FAERS AUCR AUCR1 AUCR2 OR Total Case G12 G23 OR Total Case G12 G23 
omeprazole Fluconazole clonidine 5.67E-03 2.68E-03 9.35 5.06 1.45 18.46 37 24 2.64E-12 4.18E-01 6.41 105 19 1.38E-01 2.00E-01 
esomeprazole Fluconazole clonidine 1.40E-04 7.14E-12 8.51 5.17 1.35 36.67 28 22 1.34E-04 4.35E-02 13.04 100 31 1.09E-01 7.64E-06 
a- omeprazole/ 
esomeprazole Clonidine fluconazole           24.21   7.77E-13 6.88E-02 8.73   1.15E-02 1.22E-05 
esomeprazole Fluconazole acetaminophen 4.22E-14 5.38E-04 5.20 5.17 1.01 18.77 279 182 5.13E-05 5.06E-02 5.20 922 140 3.75E-07 9.67E-02 
esomeprazole Fluconazole trazodone 6.57E-04 2.78E-06 5.19 5.17 1.01 17.31 71 45 3.83E-24 8.04E-01 10.45 68 18 1.22E-01 1.04E-01 
esomeprazole fluconazole fentanyl 7.06E-08 2.28E-15 5.18 5.17 1.01 39.09 54 43 2.88E-24 4.96E-01 8.09 303 66 6.21E-18 2.30E-01 
esomeprazole fluconazole metoclopramide 3.40E-06 1.29E-09 5.17 5.17 1.00 36.67 42 33 1.20E-09 9.91E-02 6.46 368 67 1.66E-01 9.00E-01 
esomeprazole fluconazole tramadol 1.76E-02 3.69E-10 5.17 5.17 1.00 15.88 44 27 4.70E-03 4.40E-01 8.69 165 38 1.42E-01 2.76E-02 
esomeprazole fluconazole levofloxacin 9.02E-03 1.41E-23 5.17 5.17 1.00 16.88 43 27 1.29E-16 6.44E-01 9.15 363 87 7.19E-01 8.97E-01 
esomeprazole fluconazole ciprofloxacin 1.06E-03 4.06E-14 5.17 5.17 1.00 18.42 54 35 1.68E-05 1.00E-01 7.02 411 80 4.42E-04 2.95E-01 
omeprazole fluconazole acetaminophen 1.25E-21 4.09E-13 5.10 5.06 1.02 18.67 450 293 3.78E-48 4.57E-02 5.67 1109 181 1.28E-01 4.15E-01 
omeprazole fluconazole trazodone 4.12E-04 6.72E-16 5.08 5.06 1.01 18.26 65 42 4.48E-52 7.03E-01 12.74 141 43 4.50E-01 6.23E-04 
omeprazole fluconazole fentanyl 1.07E-05 3.97E-16 5.08 5.06 1.01 27.69 49 36 4.33E-49 5.47E-01 7.85 343 73 1.21E-03 7.31E-01 
omeprazole fluconazole paroxetine 1.69E-02 1.88E-06 5.06 5.06 1.00 18.00 28 18 1.00E-04 1.70E-01 7.38 148 30 1.94E-03 9.55E-01 
omeprazole fluconazole diclofenac 2.42E-02 2.04E-03 5.06 5.06 1.00 17.78 25 16 8.62E-08 2.30E-01 6.61 97 18 3.57E-01 7.10E-03 
omeprazole fluconazole levofloxacin 2.09E-03 1.93E-37 5.06 5.06 1.00 17.50 55 35 6.35E-25 4.23E-01 9.94 502 128 6.16E-02 5.28E-07 
loratadine fluconazole tramadol 2.11E-03 1.37E-03 3.13 2.65 1.06 22.00 32 22 4.50E-09 6.91E-01 7.52 68 14 8.59E-01 5.49E-01 
loratadine clonidine metoclopramide 2.70E-02 2.40E-02 2.86 2.84 1.00 26.67 11 8 1.74E-05 6.80E-01 7.81 33 7 3.91E-04 8.40E-01 
loratadine clonidine levofloxacin 1.27E-03 4.50E-03 2.84 2.84 1.00 N/A 10 10 7.61E-05 6.96E-01 8.06 46 10 4.58E-01 7.91E-01 
loratadine fluconazole fentanyl 2.32E-02 2.64E-04 2.68 2.65 1.02 35.00 9 7 3.63E-16 6.77E-01 7.46 88 18 1.61E-05 6.22E-01 
loratadine fluconazole acetaminophen 2.57E-19 1.31E-04 2.67 2.65 1.04 39.34 148 118 3.97E-86 3.21E-03 5.86 262 44 1.19E-03 3.68E-01 
loratadine fluconazole metoclopramide 2.50E-03 1.17E-04 2.67 2.65 1.00 100.00 11 10 1.49E-07 2.06E-01 8.88 64 15 1.28E-01 4.15E-01 
loratadine fluconazole levofloxacin 2.14E-04 1.02E-09 2.65 2.65 1.00 80.00 18 16 9.40E-07 6.35E-02 10.24 115 30 4.97E-02 1.16E-01 
venlafaxine tramadol clonidine 5.74E-03 2.47E-07 2.30 2.03 1.06 36.67 14 11 5.97E-08 1.18E-01 11.38 71 20 6.26E-03 5.49E-03 
venlafaxine tramadol fentanyl 1.83E-05 2.69E-29 2.06 2.03 1.03 73.34 25 22 1.30E-22 4.55E-02 15.96 203 72 9.58E-21 1.33E-09 
venlafaxine tramadol trazodone 6.48E-06 7.86E-13 2.06 2.03 1.03 18.00 112 72 2.39E-25 2.05E-01 7.72 281 59 1.64E-05 1.97E-03 
venlafaxine tramadol metoclopramide 7.86E-04 8.81E-16 2.05 2.03 1.02 28.57 27 20 3.39E-16 3.34E-01 12.16 149 44 1.56E-09 4.52E-05 
venlafaxine tramadol ciprofloxacin 1.60E-02 3.45E-12 2.05 2.03 1.00 16.92 35 22 1.30E-20 5.76E-01 14.51 90 30 8.54E-05 5.01E-02 
venlafaxine tramadol acetaminophen 7.15E-17 1.05E-14 2.05 2.03 1.00 17.87 390 250 1.52E-59 1.07E-01 6.10 766 133 2.09E-16 1.04E-04 
Table 4.2 Top 28 3-way drugs interaction combination. G12 and G23 means the p-value of odds ratio compared taken 1 of 3 drugs vs 
2 of 3 drugs, and taken 2 of 3 drugs and 3 of 3 drugs. a. Combine analysis: treated omeprazole and esomeprazole as same drug. 
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The AUCRs of omeprazole due to the inhibition by clonidine and fluconazole 
alone or together were estimated from literature data using mechanistic static 
interaction models (Ito et al., 2005). Omeprazole is a racemic mixture of R- and S-
omeprazole. While both enantiomers are metabolized by CYP2C19 and CYP3A (Figure 
4.6), the fm’s for each pathway are slightly different (Table 4.3). Fluconazole is a well-
known CYP2C19 and CYP3A inhibitor with a median ki value of 5.075 µM and 13.25 µM, 
respectively (Moody, Griffin, Mather, McGinnity, & Riley, 1999; Niwa, Shiraga, & Takagi, 
2005; Wienkers et al., 1996). The ki of clonidine for CYP3A is 0.15 µM (Tanaka, 
Nakamura, Inomata, & Honda, 2006). Incorporating these values into the IVIVE model 
(Equation 4), predicts AUCRs of R- and S-omeprazole of 1.45 and 1.35, respectively, after 
the clonidine inhibition, and 5.06 and 5.17 after fluconazole inhibition. Following co-
administration of the 3 drugs, the AUCRs of R- and S-omeprazole are predicted to be 
9.35 and 8.51, respectively. Alternatively, the fm of omeprazole can also be estimated 
from pharmacogenetics PK study. Venkatakrishnan et al. calculated the fm of 
omeprazole from AUCR of CYP2C19 extensive metabolizer and poor metabolizer 
(Venkatakrishnan, Obach, & Rostami-Hodjegan, 2007; Yasui-Furukori et al., 2004) (fm = 
0.87 for CYP2C19). Using this fm, the AUCR estimated from IVIVE is predicted to be 1.14 
after the clonidine inhibition; 5.99 after fluconazole inhibition; and 7.69 after inhibition 
by both drugs. 
4.4 Discussion 
Using the MDCM, we mined the high dimensional drug interactions among 30 
common drugs in two independent health record databases. We identified a number of 
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high-dimensional drug interactions that have increased risk of myopathy in both 
databases. This model further reveals interesting differences in the drug-count response 
relationship in the two databases. In the FAERS, the maximum myopathy risk goes to 
almost 1.0 as the dimension of drug combinations increases. Thus, a patient would be 
expected to experience a myopathy event if he/she takes a large number of drugs. On 
the other hand, the maximum myopathy risk in the INPC-CDM data is 0.72. However, 
because it was estimated from a case-control study, this number cannot be simply 
interpreted as a population maximum myopathy risk. Our 1:10 case control design has a 
higher myopathy case frequency (0.09) than the INPC-CDM population myopathy risk 
(0.067) reported previously (Duke et al., 2012). Hence, we anticipate that the population 
maximum HDDI myopathy risk in the INPC-CDM data is less than 0.72. While we observe 
that the maximum myopathy risk is higher in the FAERS database than in the INPC-CDM 
database, it is extremely striking that the frequency in FAERS approaches one. Although 
the maximum myopathy risk in the INPC-CDM data is lower than that of FAERS, it is still 
an extremely common ADE.  
Among the statistically significant three-way drug interactions identified from 
MDCM and validated by two databases, more stringent sequential comparisons are 
further conducted between 1-drug vs 2-drug and 2-drug vs 3-drugs. We further 
demonstrated that omeprazole, clonidine, and fluconazole, exhibited statistically 
significantly increased myopathy risk from single drug to three-drug combination in both 
databases.  
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In parallel to our MDCM model, we evaluated the potential CYP PK interactions among 
the 30 drugs. In the IVIVE high dimensional drug interaction prediction, one drug acts as 
the substrate and the other drugs are assumed to be reversible inhibitors of CYP 
enzymes. Substrate AUCR changes were predicted based the curated in vitro PK data. 
The maximum predicted AUCR was reached with three-drug combinations. In contrast, 
the maximum HDDI myopathy risk observed in the two medical record databases did 
not occur until five drugs were co-administered. This suggests that additional 
mechanisms are responsible for the increased risk of myopathy observed with HDDIs. 
For instance, we have previously shown that the increased risk myopathy with co-
administration of loratadine and simvatstain is due to a pharmacodynamic mechanism 
in the muscle cell (Han et al., 2015). We have also shown that the increased risk of 
myopathy observed when chloroquine is co-administered with simvastatin is the result 
of increased lysosomal OATP1B1 protein degradation (Alam et al., 2016). 
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Figure 4.6 hepatic metabolism drugs interaction between omeprazole, clonidine, and fluconazole. 
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Drug DBID 1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A unknown CYP pathway Fe 
Alprazolam db00404 - 4.50% - - 9.80% 1.20% - - 53.00% 31.50% 20.00% 
Duloxetine db00476 41.27% - - - - - 50.06% - - 8.67% - 
esomeprazole db00736 - - - - - 73.00% - - 27.00% - 0.50% 
lansoprazole db00448 - - - - - 67.90% - - 32.10% - - 
Loratadine db00455 - - - - - 20.00% 10.00% - 70.00% - 5.00% 
omeprazole db00338 - - - - - 68.00% - - 32.00% - - 
simvastatin db00641 - - - - - - - - 52.50% 47.50% 10.00% 
Tramadol db00193 14.08% - - - 8.18% 8.89% 23.89% 10.32% 34.63% - 20.00% 
Venlafaxine db00285 0.47% - - - 6.01% - 87.39% - 6.13% - 5.50% 
Table 4.3 Drugs fm and fe 
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As the risk of myopathy consistently increased among 2-way and 3-way 
combinations of omeprazole, clonidine, and fluconazole, we closely examined the 
predicted AUCR using IVIVE for these combinations. Compared to the 1.5-5 fold increase 
in AUCR of R- and S-omeprazole when inhibited by only one drug, either clonidine or 
fluconazole, the co-administration of both drugs with omeprazole led to an AUCR of 8.5-
9.4. As fm is a critical component of predicting the extent of interaction, we evaluated 
the interaction using both in vitro data and data from clinical pharmacogenetic study of 
CYP2C19 to determine omeprazole’s fm. We estimated fmCYP2C19 (0.68) from in vitro 
data mining (McGinnity, Parker, Soars, & Riley, 2000); Roman et al. estimated 
omeprazole clearance is decreased by 50% in CYP2C19 heterozygous patients 
(fmCYP2C19 = 0.5) (Roman et al., 2014); Venkatakrishnan et al. estimated fmCYP2C19 
(0.87) from AUCR of CYP2C19 PMs (Venkatakrishnan et al., 2007; Yasui-Furukori et al., 
2004). The different fmCYP2C19 estimation results AUCR of omeprazole inhibit by 
clonidine and fluconazole range from 7.55-11.74. Although the mechanism of 
omeprazole induced myopathy has not yet been understood, various hypotheses have 
been proposed such as the induction of auto-immune antibodies (Clark & Strandell, 
2006; Sivakumar & Dalakas, 1994), and the irreversible inhibition of potassium-hydrogen 
ATPase in the skeletal muscles (Schonhofer, Werner, & Troger, 1997).  
Recently, Sansone et al. surveyed the Italian National Network of 
Pharmacovigilance Database and found that omeprazole was more frequently involved 
in reports of myopathy than any other non-statin drug (Capogrosso Sansone et al., 
2017). From these evidences, omeprazole is the primary candidate that induced 
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myopathy. In additional, there were sixteen case reports in the literature (Jeon et al., 
2016; Visruthan, Boo, Kader, Ping, & Ong, 2012)) and summarized in a case series that 
associate the use of omeprazole with myopathy (Clark & Strandell, 2006). Among these 
sixteen cases, two were identified as Asians, but the race were not reported among the 
other cases. Similarly, in our database, the race data were incomplete and sometimes 
inaccurate. Hence, the race effect of omeprazole induces myopathy remains unknown.  
One limitation of the MDCM model is its large computational expense. Because 
of this, only a limited number of drugs (i.e. 30) could be screened for high-dimensional 
drug interactions. Thus, screening steps are required to reduce the number of drugs. 
More research is needed to increase the computational efficiency of MDCM. Future 
research will also apply the MDCM model to evaluate the drug-count response patterns 
for other ADEs.    
Although the mechanistic static model is a well-accepted screening tool for 
pharmacokinetic drug interactions, it may over- or under-estimate the extent of 
interaction. Of note, our model only included reversible inhibition and did not consider 
gut wall metabolism effects of inhibitors. Thus, we may have under-estimated the AUCR 
for orally administered drugs. While mechanistic static models have been established to 
predict the effect of mechanism based inhibitors and CYP inducers (Fahmi et al., 2008; 
Mayhew, Jones, & Hall, 2000), these models have not been validated with respect to 
high-dimensional interactions among drugs that inhibit the same enzyme. Additionally, 
interactions in other pathways, such as drug transporters, could be included using more 
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mechanistic and time-dependent modeling techniques. In addition, we utilized Cmax data 
from the literature without respect to the doses of drugs observed in the clinical records. 
This study demonstrates the power to elucidate clinically significant high-
dimensional drug interactions from clinical records. Using two unique data sets, ADE 
case reports from the FAERS and structured electronic medical record data from the 
INPC-CDM, we observed increasing trends in myopathy risk with higher medication 
burden. As a large number of DDIs are the result of PK interactions at the level of CYP 
enzymes, we also estimated the increased exposure of 9 substrate drugs in the presence 
of 2, 3, or more inhibitors. Although we demonstrated that decreased clearance of 
drugs due to CYP inhibition is one source of the increased myopathy risk among 
polypharmacy patients, this mechanism is unable to fully explain the increased risk of 
myopathy observed in subjects taking 4 or more medications. As our computational 
efficiency expands to allow for the evaluation of greater number of drugs using our 
MDCM model, additional pharmacokinetic and pharmacodynamic mechanisms of 
interaction will need to be considered to further account for the increased risk of ADEs 
observed in polypharmacy patients. 
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Chapter 5. Conclusion 
In this research, we create a fm database that will help to predict drug 
interactions. These data characterize all the hepatic CYP450 metabolic pathways and 
their contributions in predicting drug interactions. We therefore further explore and 
predict the drug interactions among these 57 cancer drugs in the following case study. 
In this dissertation, we have further identified fu, Cmax and Ki,u for 32 out of 57 cancer 
drugs through the PubMed literature review. Then, each drugs pair selected from 32 
drugs are further evaluated twice in order to predict their interactions. Each time, one 
drug serves as substrate and the other one serves as inhibitor, and vice-versa. Following 
the FDA DDI guideline(Food & Administration, 2012) and expert experience, an AUCR 
>1.5 is regarded as the moderate or strong DDI evidence. Based on our PBPK model 
based DDI predictions, we find 97 drug pairs with AUCR more than 1.5. After been 
validated in DrugBank, Drugs.com and PubMed, 33 pairs have at least one clear DDIs 
evidence mentioned in DrugBank or Drugs.com or in PubMed. 
Using the MDCM with IVIVE, we mined the high dimensional drug interactions 
among 30 common drugs in two independent health record databases. We identified a 
number of high-dimensional drug interactions that have increased risk of myopathy. The 
predicted AUCR demonstrated the maximum inhibition in CYP enzymes when the 
dimension of drug combination reaches three. In contrast, the maximum HDDI 
myopathy risk observed in the two medical record databases did not occur until five 
drugs were co-administered. This suggests that additional mechanisms are responsible 
for the increased risk of myopathy observed with HDDIs. Using more stringent 
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sequential comparisons between 1-drug vs 2-drug and 2-drug vs 3-drugs, we further 
demonstrated that omeprazole, clonidine, and fluconazole, exhibited statistically 
significantly increased myopathy risk from single drug to three-drug combination in both 
databases. Compared to the 1.5-5 fold increase in AUCR of R- and S-omeprazole when 
inhibited by only one drug, either clonidine or fluconazole, the co-administration of both 
drugs with omeprazole led to an AUCR of 8.5-9.4. As fm is a critical component of 
predicting the extent of interaction, we evaluated the interaction using both in-vitro 
data and data from clinical pharmacogenetic study of CYP2C19 to determine 
omeprazole’s fm (Venkatakrishnan et al., 2007; Yasui-Furukori et al., 2004). We further 
review the risk of myopathy with omeprazole. There are case reports since 1992 and 
case series published by the World Health Organization (WHO) that the use of 
omeprazole may be associated with myopathy (Clark & Strandell, 2006). Recently, 
Sansone et al use Italian National Network of Pharmacovigilance Database to identify 
that omeprazole could be involved in reports of myopathy more frequently than any 
non-statin drug (Capogrosso Sansone et al., 2017). For the first time, we demonstrate 
both clinical impact and pharmacologic mechanism for the omeprazole, clonidine, and 
fluconazole interaction induced myopathy where myopathy has been report associated 
with omeprazole and fluconazole alone in SIDER.  
Finally, we propose a random control approach based nested case-control design 
for EMR/EHR analyses. For a case, random controls are matched patients who have 
same risk factors as the case. While, compared with the dynamic/super control selection 
approach, random control selection relaxes the matching by the cases’ index time 
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restriction, which is the most computational expensive step. We evaluate the 
performances of random control and other control selection approaches by using the 
OMOP gold standard and the INPC-CDM data. The area AUC values by using these 
disproportionality measurements. We observe the random control (AUC: 0.572 – 0.597) 
and all patients analysis (AUC: 0.595 – 0.619) have modest well AUCs. While, the 
dynamic controls (AUC: 0.492 -0.539) and super controls (AUC: 0.482 – 0.538) have less 
powerful detection capability. Through AUC analyses, the random control selection has 
a modest well detection capability. Its average AUC value is only less than the best 
average AUC value. 
In the future, with random control selection, all other ADEs can share same 
controls; we are looking forward to investigating other drug-count responsive patterns 
for other ADEs. Also, because of the limitation of the computation expense MDCM, it 
computationally can handle only a limited number of drugs (i.e. 30). Thus, screening 
steps are required to reduce the number of drugs. More research is needed to increase 
the computational efficiency of MDCM. 
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